<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7472297</article-id><article-id pub-id-type="doi">10.3390/v12080852</article-id><article-id pub-id-type="publisher-id">viruses-12-00852</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Contribution of Human Retroviruses to Disease Development&#x02014;A Focus on the HIV&#x02013; and HERV&#x02013;Cancer Relationships and Treatment Strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5074-1785</contrib-id><name><surname>Liu</surname><given-names>Ching-Hsuan</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00852">1</xref><xref ref-type="aff" rid="af2-viruses-12-00852">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0666-4361</contrib-id><name><surname>Grandi</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="af3-viruses-12-00852">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1998-6127</contrib-id><name><surname>Palanivelu</surname><given-names>Lalitha</given-names></name><xref ref-type="aff" rid="af4-viruses-12-00852">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4849-0980</contrib-id><name><surname>Tramontano</surname><given-names>Enzo</given-names></name><xref ref-type="aff" rid="af3-viruses-12-00852">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7374-7234</contrib-id><name><surname>Lin</surname><given-names>Liang-Tzung</given-names></name><xref ref-type="aff" rid="af1-viruses-12-00852">1</xref><xref ref-type="aff" rid="af5-viruses-12-00852">5</xref><xref rid="c1-viruses-12-00852" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-viruses-12-00852"><label>1</label>Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; <email>d119107007@tmu.edu.tw</email></aff><aff id="af2-viruses-12-00852"><label>2</label>Department of Microbiology &#x00026; Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada</aff><aff id="af3-viruses-12-00852"><label>3</label>Department of Life and Environmental Sciences, University of Cagliari, Monserrato, 09042 Cagliari, Italy; <email>nicole.grandi2@gmail.com</email> (N.G.); <email>tramon@unica.it</email> (E.T.)</aff><aff id="af4-viruses-12-00852"><label>4</label>International Master Program in Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; <email>lalitaniyaa62@gmail.com</email></aff><aff id="af5-viruses-12-00852"><label>5</label>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan</aff><author-notes><corresp id="c1-viruses-12-00852"><label>*</label>Correspondence: <email>ltlin@tmu.edu.tw</email>; Tel.: +886-2-2736-1661 (ext. 3911)</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>852</elocation-id><history><date date-type="received"><day>01</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Animal retroviruses are known for their transforming potential, and this is also true for the ones hosted by humans, which have gathered expanding attention as one of the potent causative agents in various disease, including specific cancer types. For instance, Human T Lymphotropic virus (HTLV) is a well-studied class of oncoviruses causing T cell leukemia, while human immunodeficiency virus (HIV) leads to acquired immunodeficiency syndrome (AIDS), which is linked to a series of defining cancers including Kaposi sarcoma, certain types of non-Hodgkin lymphoma, and cervical cancer. Of note, in addition to these &#x0201c;modern&#x0201d; exogenous retroviruses, our genome harbors a staggering number of human endogenous retroviruses (HERVs). HERVs are the genetic remnants of ancient retroviral germline infection of human ancestors and are typically silenced in normal tissues due to inactivating mutations and sequence loss. While some HERV elements have been appropriated and contribute to human physiological functions, others can be reactivated through epigenetic dysregulations to express retroviral elements and promote carcinogenesis. Conversely, HERV replication intermediates or protein products can also serve as intrinsic pathogen-associated molecular patterns that cause the immune system to interpret it as an exogenous infection, thereby stimulating immune responses against tumors. As such, HERVs have also been targeted as a potential internal strategy to sensitize tumor cells for promising immunotherapies. In this review, we discuss the dynamic role of human retroviruses in cancer development, focusing on HIV and HERVs contribution. We also describe potential treatment strategies, including immunotherapeutic targeting of HERVs, inhibiting DNA methylation to expose HERV signatures, and the use of antiretroviral drugs against HIV and HERVs, which can be employed as prospective anti-cancer modalities.</p></abstract><kwd-group><kwd>human endogenous retroviruses</kwd><kwd>human immunodeficiency virus</kwd><kwd>carcinogenesis</kwd><kwd>cancer treatment</kwd><kwd>antiviral strategies</kwd><kwd>immunotherapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-12-00852"><title>1. Introduction</title><p>Retroviruses are a large group of viruses that cause a wide range of diseases, including cancers. Accordingly, the well-described transforming nature of animal retroviruses led to their original definition as &#x0201c;RNA tumor viruses&#x0201d; [<xref rid="B1-viruses-12-00852" ref-type="bibr">1</xref>]. Currently, there are two exogenous retroviruses affecting human health: human immunodeficiency virus (HIV) and human T lymphotropic virus (HTLV). While HTLV is a &#x0201c;classical&#x0201d; oncovirus, causing T cell leukemia as its main etiological manifestation, HIV infection is responsible for acquired immunodeficiency syndrome (AIDS), which is accompanied by a number of comorbidities, including increased incidence of different types of cancers [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>].</p><p>Of note, in addition to the above exogenous retroviruses, the DNA of all vertebrate contains endogenous retroviruses (ERVs), which are ancient traces of past infections found as viral footprints in the genome of the various species. The ones found in humans, the human endogenous retroviruses (HERVs), represent as approximately 8% of the human genome and have been recently classified into 39 main groups [<xref rid="B3-viruses-12-00852" ref-type="bibr">3</xref>]. These viral footprints are virus-associated sequences that closely resemble present-day retroviral (e.g., HIV) elements, including the 5&#x02019; and 3&#x02019; long terminal repeats (LTR), and the coding genes <italic>gag</italic>, <italic>pro-pol</italic>, and <italic>env</italic> [<xref rid="B4-viruses-12-00852" ref-type="bibr">4</xref>]. However, their long-time persistence in the host genome has led to the accumulation of mutations as well as insertions and deletions, which have generally affected their capacity to produce infectious virions [<xref rid="B5-viruses-12-00852" ref-type="bibr">5</xref>].</p><p>Viruses of the <italic>Retroviridae</italic> family typically contain two copies of positive-sense single-stranded RNA (ssRNA) genome at their core and are surrounded by host-derived lipid membrane inserted with the <italic>env</italic> gene-encoded glycoproteins (e.g., gp160 in the case of HIV, which is processed to yield the surface gp120 and the transmembrane gp41 [<xref rid="B6-viruses-12-00852" ref-type="bibr">6</xref>]). The Env glycoproteins mediate the entry steps of HIV into the targeted host cells, whereas the viral enzymatic activities (reverse transcriptase (RT), RNase H, integrase (IN), and protease (PR)) encoded by the <italic>pro-pol</italic> gene are crucial to viral replication [<xref rid="B6-viruses-12-00852" ref-type="bibr">6</xref>]. Retroviruses are characterized by their ability to perform reverse transcription of their ssRNA genome and integrating them into the host chromosomal DNA [<xref rid="B7-viruses-12-00852" ref-type="bibr">7</xref>]. As such, ERVs are considered molecular remnants of ancient exogenous retroviruses resulted from their germ line infection and integration in vertebrate ancestors approximately over 100 million years ago [<xref rid="B8-viruses-12-00852" ref-type="bibr">8</xref>]. </p><p>In this review, we have included in the first part the HIV&#x02013;cancer relationship and the associated use of antiretroviral therapy (ART) to demonstrate the potential applications of ART as anti-cancer strategies relevant to retroviruses due the solid evidence in this field, whereas the second part focuses on the new implication of HERV and the development of novel anti-cancer strategies for HERV-associated cancer scenarios. Although HTLV is also an onco-retrovirus, evidence for treating HTLV-associated T cell leukemia with antiretroviral therapy remains limited. Currently, only the combination of interferon (IFN)-&#x003b1; and zidovudine showed some benefits in patients with T cell leukemia, and the underlying mechanism and the antiviral contribution of zidovudine require further investigation (as reviewed by Marino-Merlo et al. [<xref rid="B9-viruses-12-00852" ref-type="bibr">9</xref>] and Futsch et al. [<xref rid="B10-viruses-12-00852" ref-type="bibr">10</xref>]). Therefore, the following discussion will be focused on HIV and HERV.</p></sec><sec id="sec2-viruses-12-00852"><title>2. HIV-Associated Cancers: Classification and Epidemiology</title><p>When the first clusters of AIDS epidemics were observed, at the beginning of the 1980s, the manifestations associated with immunodeficiency included Kaposi&#x02019;s sarcoma, aggressive B cell lymphomas, and invasive cervical cancer. These malignancies were commonly found in AIDS patients and thus became the &#x0201c;AIDS-defining&#x0201d; cancers when observed in HIV-infected individuals [<xref rid="B11-viruses-12-00852" ref-type="bibr">11</xref>]. In addition to AIDS-defining cancers, a number of other malignancies are known to be associated to HIV infection, even if non-AIDS-defining, showing an increased incidence among HIV patients. These HIV-associated cancers include lung cancer, hepatocellular carcinoma, Hodgkin&#x02019;s lymphoma, oropharyngeal cancers, and anal and genital cancers [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. The overall augmented cancer risk in HIV-infected individuals is driven by multiple factors. In most of these conditions, HIV does not have a direct transforming role, but the effects of its infection, especially on the host immune system, create a dysregulated environment triggering cancer development by both immunosuppression, which can aid in the immune evasion of oncoviruses and cancer cells, and chronic inflammation, which promotes cellular proliferation hence tumorigenesis [<xref rid="B12-viruses-12-00852" ref-type="bibr">12</xref>,<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>]. Behavioral aspects of the HIV-infected individuals, such as the increased rate of co-exposure to oncoviruses in people with multiple sexual contacts or drug users, also contribute to the increased cancer risk [<xref rid="B14-viruses-12-00852" ref-type="bibr">14</xref>].</p><p>Notably, the development of effective antiretroviral drugs (ARVs) has led to a significant reduction of AIDS-defining cancers (discussed below). In turn, the concomitant improvement of treated patients&#x02019; survival has doubled the number of people living with AIDS, and a large proportion of them is currently in the age range that is associated with augmented cancer risk [<xref rid="B15-viruses-12-00852" ref-type="bibr">15</xref>]. As a consequence of an aging HIV-infected population, the occurrence of both HIV-associated (non-AIDS-defining) cancers and common incidental cancers has increased, becoming the main cause of death in developed countries [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. It is noteworthy that adolescents and young adults living with AIDS also have an increased risk of developing both AIDS-defining and non-AIDS-defining cancers compared to HIV-negative individuals of the same age, and their relatively low adherence to ARVs could aggravate the occurrence of malignancies [<xref rid="B16-viruses-12-00852" ref-type="bibr">16</xref>].</p></sec><sec id="sec3-viruses-12-00852"><title>3. AIDS-Defining HIV-Associated Cancers</title><p>The first cancer historically connected to AIDS&#x02019; presence was Kaposi&#x02019;s sarcoma, characterized by lesions on the skin and other organs, including oral mucosa, gastrointestinal tract, lymph nodes, lungs, and bones [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. Kaposi&#x02019;s sarcoma is caused by human herpesvirus 8, also known as Kaposi&#x02019;s sarcoma-associated herpesvirus (KSHV). KSHV does not require HIV infection to develop Kaposi&#x02019;s sarcoma, but the immune dysregulation induced by HIV affects the immunologic control of KSHV and other oncoviruses found in HIV patients, sustaining carcinogenesis. Accordingly, the risk of Kaposi&#x02019;s sarcoma in HIV patients is inversely related to their CD4+ T cell count, although a few patients with relatively high CD4+ T cell count still had persistent Kaposi&#x02019;s sarcoma [<xref rid="B17-viruses-12-00852" ref-type="bibr">17</xref>]. The second group of AIDS-defining cancer is represented by aggressive B cell non-Hodgkin&#x02019;s lymphomas [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. Of which, primary central nervous system lymphoma and plasmablastic lymphoma often consist of cells infected by Epstein Barr virus (EBV), while Burkitt&#x02019;s lymphoma and diffuse large B cell lymphoma are mainly negative for EBV [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. Although the overall incidence of non-Hodgkin lymphomas in HIV patients showed a pronounced decrease with the advent of effective antiretroviral treatments, it still remains 10-fold higher as compared to uninfected population [<xref rid="B18-viruses-12-00852" ref-type="bibr">18</xref>,<xref rid="B19-viruses-12-00852" ref-type="bibr">19</xref>]. The third and last AIDS-defining malignancy is invasive cervical cancer, whose risk is increased in HIV-infected women, being associated with age but not with CD4+ T cell count [<xref rid="B20-viruses-12-00852" ref-type="bibr">20</xref>]. Overall, almost all cervical cancers arise from human papilloma virus (HPV) oncogenesis, and the concomitant presence of HIV may augment its incidence by affecting the host immune response and thus preventing the clearance of HPV infection [<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>].</p></sec><sec id="sec4-viruses-12-00852"><title>4. Other HIV-Associated Cancers</title><p>Besides the above AIDS-defining cancers, HIV infection is associated with increased incidence of a number of other malignancies. The most frequent HIV-associated cancers include lung cancer, hepatocellular carcinoma, Hodgkin&#x02019;s lymphoma, oropharyngeal cancers, as well as genital and anal cancers [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>]. In the majority of cases, oncogenesis is mediated by the co-infection with an oncovirus, in which HIV-induced immune dysregulation facilitates its immune evasion and tumorigenesis.</p><p>A great proportion of HIV-associated cancers affecting the oropharynx, genitals and anus are linked to HPV infection as well [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>,<xref rid="B21-viruses-12-00852" ref-type="bibr">21</xref>]. In fact, as mentioned for cervical cancer, HIV-infected individuals present immunosuppression that is linked to a higher risk to establish a chronic HPV infection and develop pre-malignant high-grade intraepithelial lesions [<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>,<xref rid="B22-viruses-12-00852" ref-type="bibr">22</xref>]. As for hepatocellular carcinoma, its etiological agent hepatitis virus B and C (HBV and HCV, respectively) are frequently transmitted with the same route of HIV, and thus often co-infect with HIV. This increases the incidence of hepatocellular carcinoma in HIV patients, with similar cancer progression in non-HIV-infected individuals with chronic viral hepatitis [<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>]. Concerning non-AIDS defining lymphomas associated to HIV infection, they are also often caused by the concomitant infection with transforming viruses, such as EBV and KSHV. Pharmacological therapy against HIV has not been able to reduce the incidence of Hodgkin lymphoma in infected individuals, but recent findings suggest that prolonged ART seems to reduce the associated risk [<xref rid="B23-viruses-12-00852" ref-type="bibr">23</xref>]. Overall, besides a higher incidence of lymphomas, individuals infected with HIV tend to show extranodal and central nervous system involvement [<xref rid="B24-viruses-12-00852" ref-type="bibr">24</xref>] and elevated cancer-specific mortality [<xref rid="B25-viruses-12-00852" ref-type="bibr">25</xref>] as compared to the general population. Lung cancer is another malignancy reported to have higher incidence in HIV-infected individuals than the uninfected population [<xref rid="B26-viruses-12-00852" ref-type="bibr">26</xref>]. There is a three-times increased risk in HIV-infected individuals, which depends in part on a high prevalence of smokers [<xref rid="B27-viruses-12-00852" ref-type="bibr">27</xref>], but also on HIV-related factors such as elevated susceptibility to pneumonia and chronic obstructive pulmonary disease, which contribute to a higher risk of lung malignancies [<xref rid="B26-viruses-12-00852" ref-type="bibr">26</xref>,<xref rid="B28-viruses-12-00852" ref-type="bibr">28</xref>]. The associated mortality, however, seems not to be linked to either HIV load or CD4+ T cell count [<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>,<xref rid="B29-viruses-12-00852" ref-type="bibr">29</xref>]. In addition to the above HIV-associated tumors, the presence of the infection augments the risk of incidental cancers as well, including colon, breast, prostate, and squamous-cell skin cancers [<xref rid="B2-viruses-12-00852" ref-type="bibr">2</xref>].</p></sec><sec id="sec5-viruses-12-00852"><title>5. Immunotherapeutic Strategies Targeting HIV for Cancer Treatment</title><p>Given the clear association between HIV infection and the increased incidence of human malignancies, a number of prevention and therapeutic strategies have been proposed. First of all, given that most HIV-associated tumors depend on co-infection with known oncoviruses, a significant cancer prevention clue is represented by the vaccinations available against the oncoviruses, such as HPV and HBV for cervical and hepatocellular cancers, respectively. Similarly, screening procedures are crucial for cancer prevention and early diagnosis, not only in HIV-infected patients but also in the general population. Another important action is the early diagnosis of HIV infection, allowing for the prompt initiation of effective ART before the drastic reduction of CD4+ T cell count. In fact, growing evidence suggests that early and uninterrupted ART can reduce the risk of cancer associated with HIV infection, restoring CD4+ T cell count and limiting oncoviruses&#x02019; immune evasion [<xref rid="B15-viruses-12-00852" ref-type="bibr">15</xref>]. Accordingly, the risk of cancer was decreased by approximately two-thirds in HIV patients who started ART at a CD4+ T cell count higher than 500 cells/mm<sup>3</sup> [<xref rid="B13-viruses-12-00852" ref-type="bibr">13</xref>]. ART is an effective immunotherapy for AIDS-defining cancers, and immunotherapeutic strategies based on monoclonal antibodies, IFN, cytokines and immunomodulatory drugs have also shown efficacy in HIV-associated malignancies [<xref rid="B30-viruses-12-00852" ref-type="bibr">30</xref>]. Finally, the prevention of behavioral factors that increase HIV-associated cancer incidence, such as smoking for lung cancer or unprotected sex for sexually transmitted oncoviruses, can play an important role in reducing the incidence of these malignancies in HIV-infected individuals.</p></sec><sec id="sec6-viruses-12-00852"><title>6. The Physiological Implications of HERV Elements</title><p>As mentioned above, ERVs are viral footprints that are found in the host genomes. Over the time of evolution, integrated ERVs can be either lost or fixed (when the frequency of inserted ERV becomes 100% in the population), if the elements are beneficial for the host, as a result of natural selection and random mutations [<xref rid="B8-viruses-12-00852" ref-type="bibr">8</xref>]. Owing to their ability to integrate into the host genome, ERV sequences have important implication in host phenotypic effects that can have consequences in the context of physiological functions and diseases [<xref rid="B31-viruses-12-00852" ref-type="bibr">31</xref>]. For example, the syncytins in humans, namely syncytin-1 encoded by a HERV-W provirus <italic>env</italic> and syncytin-2 encoded by a HERV-FRD provirus <italic>env</italic>, are thought to have been acquired by the primates many millions ago (~25 million years ago for syncytin-1 and &#x0003e;40 million years ago for syncytin-2) [<xref rid="B32-viruses-12-00852" ref-type="bibr">32</xref>,<xref rid="B33-viruses-12-00852" ref-type="bibr">33</xref>] and are essential for placental morphogenesis. It has also been proposed that the syncytins can have immunomodulatory functions, including immunosuppression [<xref rid="B34-viruses-12-00852" ref-type="bibr">34</xref>] and the inhibition of Th1 cytokine production [<xref rid="B35-viruses-12-00852" ref-type="bibr">35</xref>], possibly through the putative immunosuppressive domain in their transmembrane subunit. The overall effect is thought to contribute to the physiological maternal tolerance for the fetus during pregnancy [<xref rid="B34-viruses-12-00852" ref-type="bibr">34</xref>,<xref rid="B35-viruses-12-00852" ref-type="bibr">35</xref>,<xref rid="B36-viruses-12-00852" ref-type="bibr">36</xref>]. Owing to their critical physiological roles in the placenta, this domestication and appropriation of the HERV Envs exerts a positive selection for gene fixation or retention along the primate evolution, observing high degree of conservation and very limited human polymorphisms [<xref rid="B36-viruses-12-00852" ref-type="bibr">36</xref>,<xref rid="B37-viruses-12-00852" ref-type="bibr">37</xref>].</p><p>In addition, HERVs play a role in the regulation of human gene expression in several aspects. HERV elements serve as crucial regulatory factors for the pluripotency in embryonic stem cells [<xref rid="B38-viruses-12-00852" ref-type="bibr">38</xref>] and are expressed at varied levels in normal human tissues [<xref rid="B1-viruses-12-00852" ref-type="bibr">1</xref>,<xref rid="B39-viruses-12-00852" ref-type="bibr">39</xref>] to facilitate tissue-specific gene expression. Furthermore, it is recently revealed that HERV-derived molecules modulate the innate immunity [<xref rid="B4-viruses-12-00852" ref-type="bibr">4</xref>], which can elicit both positive antiviral protection against exogenous viruses and negative autoimmune and inflammatory disease-inducing effects (further discussed below). These observations highlight the importance of HERV as a subject of study to unravel the genetic evolution of various species, and more intriguingly, for deciphering the pathophysiological development of illnesses and even be potentially explored as therapeutic targets for the treatment of many present day diseases.</p></sec><sec id="sec7-viruses-12-00852"><title>7. HERV Activation and the Paradigm of HERV in Cancers</title><p>In most tissues, HERVs are transcriptionally silenced by CpG methylation catalyzed by DNA methylase-1 [<xref rid="B40-viruses-12-00852" ref-type="bibr">40</xref>]. The aberrant expression of HERV has been found in a number of human diseases, such as cancers [<xref rid="B41-viruses-12-00852" ref-type="bibr">41</xref>], autoimmune diseases [<xref rid="B42-viruses-12-00852" ref-type="bibr">42</xref>], and neurological diseases [<xref rid="B43-viruses-12-00852" ref-type="bibr">43</xref>], possibly suggesting their role in pathogenesis. Current literature suggests that HERV can be activated by a plethora of microenvironmental stimuli such as hormones, cytokines, epigenetic modifications or exogenous microorganisms [<xref rid="B44-viruses-12-00852" ref-type="bibr">44</xref>]. Interestingly, recent studies suggest that several viral infections, such as retroviruses (HIV, HTLV-1), herpesviruses (EBV, herpes simplex virus type 1 (HSV-1), KSHV), HBV, and influenza virus, can transactivate HERV [<xref rid="B45-viruses-12-00852" ref-type="bibr">45</xref>]. These findings might provide clues to the pathogenicity of certain viruses, including those that lead to long-term disease development such as autoimmune diseases and cancers. </p><p>In the case of cancer, a considerable level of early investigation has been focused on the oncogenic properties of retroviruses. Many studies attempted to illustrate the role of HERV in cancer [<xref rid="B46-viruses-12-00852" ref-type="bibr">46</xref>], as HERV elements and HERV-encoded proteins were found in a variety of cancers including melanoma, breast cancer, colorectal cancer, hepatobiliary cancers, prostate cancer, ovarian cancer, and germ cell tumors [<xref rid="B44-viruses-12-00852" ref-type="bibr">44</xref>,<xref rid="B47-viruses-12-00852" ref-type="bibr">47</xref>,<xref rid="B48-viruses-12-00852" ref-type="bibr">48</xref>]. As such, HERV elements have been proposed to be potential biomarkers for cancers and could have an implication for therapeutic intervention [<xref rid="B48-viruses-12-00852" ref-type="bibr">48</xref>]. Although the average expression of HERV appears quite homogenous among different types of cancers [<xref rid="B49-viruses-12-00852" ref-type="bibr">49</xref>], it is noteworthy that in some studies the overexpression of HERV was not found. For instance, in the analysis performed by Rooney et al., little overexpression of the &#x0201c;tumor-specific&#x0201d; HERVs (ERVH&#x02212;5, ERVH48&#x02212;1, and ERVE&#x02212;4 in the study) was found in glioma and thyroid cancer [<xref rid="B50-viruses-12-00852" ref-type="bibr">50</xref>]. In another study by Bergallo et al., while HERV-K <italic>pol</italic> was overexpressed in pediatric acute lymphoblastic leukemia (ALL) patients, the expression level was not significantly increased in those with acute myeloid leukemia (AML) [<xref rid="B51-viruses-12-00852" ref-type="bibr">51</xref>]. In contrast, Januszkiewicz-Lewandowska et al. demonstrated that HERV-K <italic>env</italic> was overexpressed in AML but not ALL [<xref rid="B52-viruses-12-00852" ref-type="bibr">52</xref>]. In both studies, HERV-W <italic>pol</italic> and <italic>env</italic> were not found to be associated with either AML or ALL [<xref rid="B51-viruses-12-00852" ref-type="bibr">51</xref>,<xref rid="B52-viruses-12-00852" ref-type="bibr">52</xref>]. These examples suggest that HERV elements may not be overexpressed in all cancer types, and that different groups and different parts of HERV may be activated in specific malignancies.</p><p>In addition, it remains controversial whether the presence of HERV has a direct causative role or if it is simply a bystander effect of epigenetic changes, such as the hypomethylation of DNA and chromatin remodeling in the cancer cells, which could expose previously silent HERV LTRs [<xref rid="B53-viruses-12-00852" ref-type="bibr">53</xref>]. In contrast, the continued investigation has also revealed that HERVs may contribute to host defense responses against cancer [<xref rid="B54-viruses-12-00852" ref-type="bibr">54</xref>], implicating their presence as participants rather than mere bystanders. As a result, the precise role of HERV in cancer development remains to be fully clarified, but several observations described below shed light to the evolving paradigm of HERV-cancer association.</p></sec><sec id="sec8-viruses-12-00852"><title>8. HERV Contribution to Cancer at the Genome Level</title><p>Potentially oncogenic properties of HERV at the genome level include non-allelic recombination of HERV sequences, which results in chromosomal rearrangements, and HERV LTR as an alternative promotor to cellular gene expression that contributes to tumorigenesis [<xref rid="B54-viruses-12-00852" ref-type="bibr">54</xref>]. Such effects were seen in prostate cancer [<xref rid="B55-viruses-12-00852" ref-type="bibr">55</xref>], melanoma, Hodgkin&#x02019;s lymphoma, diffuse large B cell lymphoma, etc. [<xref rid="B53-viruses-12-00852" ref-type="bibr">53</xref>], where abnormal gene expression occurred due to HERV-induced translocation and/or LTR regulation. In addition, recent studies demonstrate that HERV-K(HML2) and HERV-H are concurrently expressed with pluripotent transcriptional factors NANOG, OCT-4, and SOX-2 in mesenchymal stem cells [<xref rid="B56-viruses-12-00852" ref-type="bibr">56</xref>], while HERV-W has been detected in cancer-stem like colorectal cancer cells [<xref rid="B57-viruses-12-00852" ref-type="bibr">57</xref>]. It has also been shown in melanoma cells that HERV-K(HML2) activation promotes phenotype-switching to obtain cancer stem-like features [<xref rid="B58-viruses-12-00852" ref-type="bibr">58</xref>]. It would be interesting to explore whether HERV contributes to the stemness or pluripotency in cancer stem cells in a similar way as in embryonic stem cells, i.e., through LTR and non-coding RNA (ncRNA) regulation, due to the common regulatory factors they share [<xref rid="B44-viruses-12-00852" ref-type="bibr">44</xref>].</p></sec><sec id="sec9-viruses-12-00852"><title>9. HERV Contribution to Cancer at the Protein Level</title><p>At the protein level, some Env proteins promote the tumorigenesis due to their ability to trigger cell-to-cell fusion, immunosuppression, and cell signaling pathways that are crucial for cancer development [<xref rid="B54-viruses-12-00852" ref-type="bibr">54</xref>]. In the case of breast cancer, HERV-K Env protein plays an important role in tumorigenesis and metastasis through activating the Ras-ERK pathway [<xref rid="B59-viruses-12-00852" ref-type="bibr">59</xref>]. Anti-HERV-K Env antibodies and Env-directed chimeric antigen receptor (CAR) T cells exhibited significant tumor-specific cytotoxicity and prevented metastasis in mouse xenograft models [<xref rid="B60-viruses-12-00852" ref-type="bibr">60</xref>,<xref rid="B61-viruses-12-00852" ref-type="bibr">61</xref>]. In the case of melanoma, a HERV-K(HML6) Env spliced variant, HERV-K-Mel, was found to be targeted by cytotoxic T cells in melanoma patients [<xref rid="B62-viruses-12-00852" ref-type="bibr">62</xref>]. HERV-K Env-specific CAR T cells similarly reduced tumor burden and metastasis in mouse xenograft models [<xref rid="B63-viruses-12-00852" ref-type="bibr">63</xref>]. Research in pancreatic cancer also demonstrated that HERV-K(HML2) Env regulates the Ras-ERK pathway, and knockdown of Env in vitro and in vivo reduced the growth of pancreatic cancer and metastasis [<xref rid="B64-viruses-12-00852" ref-type="bibr">64</xref>]. Finally, the <italic>env</italic>-encoded H17 protein of HERV-H was found to induce epithelial-to-mesenchymal transition (EMT) in tumor cells and recruit immunoregulatory suppressor cells, suggesting its contributory role in tumor metastasis and immune escape [<xref rid="B65-viruses-12-00852" ref-type="bibr">65</xref>]. These findings support the role of HERV Env as a tumor-promoting antigen in various types of cancers. In addition, the two spliced variants encoded by HERV-K(HML2) <italic>env</italic> gene, Rec and Np9 accessory proteins, may also play a role in transformation by binding to functional cellular proteins [<xref rid="B54-viruses-12-00852" ref-type="bibr">54</xref>], such as the transcriptional repressor of the c-MYC proto-oncogene [<xref rid="B66-viruses-12-00852" ref-type="bibr">66</xref>], proteins involved in androgen receptor repression [<xref rid="B67-viruses-12-00852" ref-type="bibr">67</xref>,<xref rid="B68-viruses-12-00852" ref-type="bibr">68</xref>], and the ligand of Numb protein X (LNX) [<xref rid="B69-viruses-12-00852" ref-type="bibr">69</xref>] involved in Notch signaling. Of note, the presence of a coding sequence for Rec putative protein has been recently reported also for HERV-K HML10 and HML6 groups [<xref rid="B70-viruses-12-00852" ref-type="bibr">70</xref>,<xref rid="B71-viruses-12-00852" ref-type="bibr">71</xref>].</p></sec><sec id="sec10-viruses-12-00852"><title>10. HERV-Induced Immune Responses&#x02014;Implication for Cancer Management</title><p>Since HERV elements are transcriptionally controlled in normal tissues, cancer environment can likely lead to their epigenetic dysregulation, possibly activating the expression of cancer-associated HERV proteins or transcripts forming double-stranded RNA (dsRNA) that could induce immune activation. HERV-encoded antigens expressed in a variety of cancers are reported to be targeted by cytotoxic T cells. In vitro, cytotoxic T cells that target HERV-K(HML6)-encoded epitope effectively lyse melanoma cells [<xref rid="B62-viruses-12-00852" ref-type="bibr">62</xref>]. Patients with a past history of seminomas and limited healthy individuals also possessed defined HERV-K(HML2)-derived epitope recognized by CD8<sup>+</sup> T cells [<xref rid="B72-viruses-12-00852" ref-type="bibr">72</xref>]. In renal cell carcinoma (RCC) patients who received hematopoietic stem-cell transplantation, CD8<sup>+</sup> T cells against an RCC-specific HERV-E antigen were produced after the transplantation and led to disease regression [<xref rid="B73-viruses-12-00852" ref-type="bibr">73</xref>]. On the contrary, humoral response against HERV usually reflects disease severity of cancer. For instance, HERV-K(HML2)-reactive antibodies were found in the sera of germ cell tumor patients and the decreased titer correlated with longer survival [<xref rid="B74-viruses-12-00852" ref-type="bibr">74</xref>]. Similarly, HERV-K(HML2) antibody reactivity in melanoma patients predicts poor prognosis [<xref rid="B75-viruses-12-00852" ref-type="bibr">75</xref>]. Antibodies specific to cancer-associated HERV could therefore serve as an indicator of disease progression and treatment effectiveness.</p><p>In conjunction with the above, HERV elements are known to trigger innate immune responses due to their viral features (viral mimicry effect). HERV antigens (including nucleic acids or proteins) that are expressed in cells may act as pathogen-associated molecular patterns (PAMPs) that could be detected by the innate immunity pattern recognition receptors (PRRs), leading to the activation of innate immune responses, including downstream pro-inflammatory signals and the induction of subsequent adaptive immune responses [<xref rid="B5-viruses-12-00852" ref-type="bibr">5</xref>,<xref rid="B76-viruses-12-00852" ref-type="bibr">76</xref>]. Essentially, the host cell interprets the induced expression of HERV molecules as a sign of infection by an exogenous virus and mounts an antiviral innate immune response. For instance, it has been shown that the ERV avian leukosis virus-derived antisense long ncRNA in the chicken embryonic fibroblasts can stimulate the TLR3 pathway to induce an antiviral innate immune state against infection by other exogenous retroviruses [<xref rid="B45-viruses-12-00852" ref-type="bibr">45</xref>]. Another example is the HERV-W Env, which can interact with receptors of the TLR4-lipopolysaccharide (LPS) pathway, including TLR4 and CD14, and induce pro-inflammatory cytokines such as IL-1&#x003b2;, IL-6, and TNF-&#x003b1; [<xref rid="B77-viruses-12-00852" ref-type="bibr">77</xref>]. Finally, with implication for cancer treatment, it has been recently shown that radiation-induced ERV-associated dsRNA transcription in mouse melanoma cells promotes the activation of the innate antiviral MDA5/MAVS/TBK1 pathway, leading to the downstream transcription of IFN-stimulated genes and resulting in anti-tumor response [<xref rid="B78-viruses-12-00852" ref-type="bibr">78</xref>]. The overall consequence of this viral mimicry is thought to weaken the cancer cells and attract cytotoxic T cells to the previously &#x0201c;immune-cold&#x0201d; tumor microenvironment, leading to tumor destruction.</p><p>In summary, HERV-encoded antigens/proteins could act as potential targets to trigger immune-mediated cascades that could be beneficial for tumor management. Provoking such mechanisms has promising significance in onco-immunotherapies.</p></sec><sec id="sec11-viruses-12-00852"><title>11. Immunotherapeutic Strategies Targeting HERV for Cancer Treatment</title><p>Due to the potential contribution of HERV expression in certain diseases, it is theoretically feasible to target HERV expression via immunotherapies such as antibodies or vaccines. For example, studies have shown that some proteins encoded by individual HERV members are found in the active multiple sclerosis (MS) patients [<xref rid="B79-viruses-12-00852" ref-type="bibr">79</xref>,<xref rid="B80-viruses-12-00852" ref-type="bibr">80</xref>]. Temelimab, also known as GNbAC1, is a humanized IgG4 monoclonal antibody targeting the HERV-W Env protein that is associated with the pathogenesis of MS [<xref rid="B81-viruses-12-00852" ref-type="bibr">81</xref>]. The therapeutic GNbAC1 antibody is designed to neutralize the impact of the HERV protein on inducing adverse pro-inflammatory responses associated with CNS inflammation and impaired remyelination. As such, neutralizing this HERV protein through GNbAC1 may elicit a desirable response against HERV-mediated pathophysiological mechanisms in MS disease progression. </p><p>This HERV-targeting approach could similarly be applied for cancer treatment, and the development of prophylactic vaccines against HERV-derived antigens has recently gained attention as a plausible strategy, although the possible use of HERV as the target for anti-cancer strategies is currently limited by the still incomplete knowledge of their role in the development and progression of the various human cancers. It has been demonstrated that HERV-derived epitopes are recognized, processed, and presented as targets for T cell immune recognition [<xref rid="B82-viruses-12-00852" ref-type="bibr">82</xref>,<xref rid="B83-viruses-12-00852" ref-type="bibr">83</xref>,<xref rid="B84-viruses-12-00852" ref-type="bibr">84</xref>]. Kraus et al. [<xref rid="B85-viruses-12-00852" ref-type="bibr">85</xref>] developed a recombinant vaccinia virus that expressed HERV-K(HML2) Env protein (MVA-HKenv) and tested it in a syngeneic mouse tumor model where HERV-K Env was expressed in the murine renal cancer cells (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells in the BALB/c mice led to metastatic lung cancer. A single vaccination with MVA-HKenv drastically resolved the pulmonary tumor nodules, suggesting the efficacy of the vaccine. The vaccinated mice displayed cell-mediated cytotoxic immunity against RLZ-HKenv cells, which can be explained by T-cell-mediated tumor cell lysis induced by the vaccine [<xref rid="B85-viruses-12-00852" ref-type="bibr">85</xref>]. This group manifested an analogous study with HERV-K(HML2) Gag protein as the promising target to elicit a long-lived T cell response against tumor in the murine model [<xref rid="B86-viruses-12-00852" ref-type="bibr">86</xref>]. A similar strategy has also been employed through adenovirus-mediated delivery of murine melanoma-associated retrovirus (MelARV) proteins Gag and Env to form virus-like particles displaying the cancer-associated MelARV Env to the immune system in mice, which could stimulate T cell response to inhibit murine colorectal tumor growth [<xref rid="B87-viruses-12-00852" ref-type="bibr">87</xref>]. Likewise, another group investigated the extent of vaccination protection in rhesus macaques against ERVs as means to target HIV- and cancer-associated endogenous retrotransposable elements. Sacha et al. immunized this primate model with Gag and Env proteins of simian endogenous retrovirus (SERV), which resulted in the polyfunctional T cell expansion and humoral immune response against both SERV-encoded proteins [<xref rid="B88-viruses-12-00852" ref-type="bibr">88</xref>]. In addition, there were no toxicity and adverse pathological findings related to vaccination, suggesting that vaccination against ERVs can safely induce immune responses and is a potential strategy for the management of HERV-associated neoplasms. Nonetheless, in spite of the fact that HERV-derived epitope-based vaccination has established a potential outcome in preclinical animal models, clinical evaluation for the safety of such a vaccination approach is required to encourage further immunotherapeutic progression targeting HERV in cancer therapy.</p></sec><sec id="sec12-viruses-12-00852"><title>12. Inhibiting DNA Methylation to Induce Anti-Tumor Response through HERV Signature Upregulation as a Cancer Treatment Strategy</title><p>As mentioned earlier, HERVs are typically transcriptionally suppressed by DNA methylation in somatic cells [<xref rid="B40-viruses-12-00852" ref-type="bibr">40</xref>], and the activation of HERV sequences through the inhibition of methyl transferases may contribute to viral mimicry effect and/or enhanced expression of neoantigens that can be detected by host immune surveillance [<xref rid="B89-viruses-12-00852" ref-type="bibr">89</xref>]. The idea of inhibiting DNA methylation represents a potential strategy to tackle cancers associated with HERV signatures. Indeed, upregulated HERV expression has been observed following treatment with the DNA methyltransferase inhibitor (DNMTi) Guadecitabine (SGI-110) in hepatoma cells that are sensitive to its anti-tumor effect [<xref rid="B90-viruses-12-00852" ref-type="bibr">90</xref>]. A similar observation was also found in ovarian cancer cells, in which a combination of the histone methyltransferase G9Ai and the DNMTi 5-aza-2&#x02019;-deoxycytidine produced a synergistic anti-tumor effect that was associated with enhanced viral mimicry from the upregulated HERV expression [<xref rid="B90-viruses-12-00852" ref-type="bibr">90</xref>]. Indeed, the use of DNMTi has been demonstrated to trigger TLR3 and MAVS-associated dsRNA sensing pathways that accompanied ERV upregulation in ovarian cancer cells, and this higher viral defense signature expression also correlates with tumor sensitivity to immune checkpoint therapy, particularly with the addition of DNMTi [<xref rid="B91-viruses-12-00852" ref-type="bibr">91</xref>]. These observations therefore support the use of DNMTi for cancers associated with HERV signatures and provide impetus to further explore their use in onco-immunotherapies.</p></sec><sec id="sec13-viruses-12-00852"><title>13. Antiviral Targeting of HERV as a Strategy for Cancer Treatment</title><p>Due to their similarity with HIV, it is theoretically possible to directly target HERVs through ARVs as an approach to defer their impact on disease progression. In the case of colorectal cancer, where HERV-H were found in almost 50% of samples [<xref rid="B92-viruses-12-00852" ref-type="bibr">92</xref>], the transcription of HERV-H was strongly linked with early immune intrusion [<xref rid="B65-viruses-12-00852" ref-type="bibr">65</xref>], microsatellite instability, lymph node invasion [<xref rid="B93-viruses-12-00852" ref-type="bibr">93</xref>], and chemotherapeutic resistance [<xref rid="B57-viruses-12-00852" ref-type="bibr">57</xref>]. The in vitro administration of cytotoxic chemotherapy in combination with antiviral therapy produced a significant anti-proliferative effect in tumors [<xref rid="B57-viruses-12-00852" ref-type="bibr">57</xref>], suggesting the need to justify the clinical impact of HERV-H blockade in colorectal cancer treatment. This points to potential usage of antiviral therapy targeting HERVs as a treatment strategy to manage cancers. There are no specific antiviral drugs developed to target HERVs so far; however, several studies began to screen FDA-approved ARVs, which may effectively inhibit HERVs due to their close association with HIV. Although initially antivirals targeting viral RT were explored, ARVs that can block all significant steps of the retroviral life cycle could be considered. This is also supported by the observation that HIV patients may have a lower risk of developing MS than the others, possibly due to the suppression of HERV by ART [<xref rid="B94-viruses-12-00852" ref-type="bibr">94</xref>].</p><p>Richa et al. tested both nucleotide RT inhibitors (NtRTI) and non-nucleotide RT inhibitors (NNtRTI) against HERV-K(HML2) RT enzyme activity in vitro. NtRTIs including abacavir, tenofovir, lamivudine, and stavudine showed significant and dose-dependent inhibition, whereas NNtRTIs including efavirenz, etravirine, and nevirapine also showed a significant inhibitory effect. Both drug groups had similar dose&#x02013;response curves and IC<sub>90</sub> values [<xref rid="B95-viruses-12-00852" ref-type="bibr">95</xref>]. To determine the effect of RT inhibitors on HML2 infectivity, the same group tested VSV-G pseudotyped HML2 infection in HeLa cells in the presence of RT inhibitors. RT inhibitors such as abacavir and zidovudine both exhibited an inhibitory effect on HML2 infection in a dose-dependent fashion [<xref rid="B95-viruses-12-00852" ref-type="bibr">95</xref>]. Contribution of RT activity in cellular transformation was also investigated in melanoma and prostate cancer cell lines. RT activity was halted by the use of NNtRTIs, such as nevirapine and efavirenz, and RT-encoding LINE-1 elements were downregulated by RNA interference (RNAi). Reduced RT activity resulted in downsized cell proliferation, enhanced morphological differentiation, and renovated gene expression patterns in vitro. Moreover, the tumorigenic phenotype of prostate carcinoma cells in the xenograft nude mice model was attenuated by the pretreatment with RT inhibitors [<xref rid="B96-viruses-12-00852" ref-type="bibr">96</xref>]. It suggests that the endogenous RT may have a pivotal role in epigenetic regulation of cell proliferation and differentiation and may serve as a novel target in cancer therapy. Alongside, the inhibitory potential of HIV protease and integrase inhibitors against HML2 has also been investigated. Protease inhibitors such as darunavir and lopinavir readily docked to the protease catalytic site, thereby inhibiting HML2 protease activity, while the integrase inhibitor raltegravir inhibited the VSV-G pseudotyped HML2 replication in a dose-dependent manner [<xref rid="B97-viruses-12-00852" ref-type="bibr">97</xref>]. This group also suggested that the replication of HML2 may be integration dependent, as the integrase inhibitor raltegravir showed a robust inhibitory effect against HML2 integrase [<xref rid="B95-viruses-12-00852" ref-type="bibr">95</xref>]. Summarizing the above reports, it appears possible that the HERVs expressed in varied cancer types can be counter-attacked by employing ARVs used in HIV treatment.</p></sec><sec sec-type="conclusions" id="sec14-viruses-12-00852"><title>14. Conclusions and Future Prospects</title><p>Like other animal retroviruses, HTLV and HIV have the potential (either directly or indirectly) to promote oncogenesis, leading to the increased incidence of a variety of human cancers in the infected population (<xref ref-type="fig" rid="viruses-12-00852-f001">Figure 1</xref>). In addition to this &#x0201c;traditional&#x0201d; scenario, HERVs are the age-old alien viruses residing in the human genome and exposing themselves in diverse human diseases. Increasing pieces of evidence indicate that the HERV gene expression is induced under specific physiological and pathological conditions. The exceptional depth at which cancer genomes are examined indicates that HERVs may have completely lost their direct tumor-causing ability due to insertional mutagenesis at the time of novel integration. Nevertheless, HERVs do still contribute to cancer pathology by distinct and often indirect mechanisms (<xref ref-type="fig" rid="viruses-12-00852-f001">Figure 1</xref>). Individual HERV members are selectively identified to possess tumor-associated properties that are significant in tumor carcinogenesis [<xref rid="B50-viruses-12-00852" ref-type="bibr">50</xref>]. However, whether HERV is a causative agent or merely a consequence of the disease is still vague, since HERV activation or HERV-encoded protein expression at the disease microenvironment alone is insufficient to prove their pathogenic potency.</p><p>With a better understanding of the link between HIV infection and HERVs, it is evident that HIV can alter HERV gene expression in specific cell types. This means that, in addition to the well-characterized increased risk for HIV-associated malignancies, HERV dysregulation by HIV infection can further prompt such a vicious cycle, providing possible oncogenes and oncoproteins absent in physiological conditions. As described above, recent investigations have pinpointed that ARVs, beside reducing the risk for HIV-associated cancers, can also affect HERV gene transcription and HERV-encoded protein function. These data have been exploited to use ARVs as an anti-cancer modality in controlling HERV activation in a cancerous condition. Further findings described here suggest that HERV elements may also be restrained by HERV-epitope-specific vaccination and by monoclonal antibody therapy, suggesting the need for the development of immunotherapy for rapidly evolving cancer types. Due to HERVs&#x02019; background of retroviral origin and partial immune tolerance, these aliens inside us have become a potential target for future onco-immunotherapy. Understanding the role of HERV in cancer progression is analogously essential to building a steady approach to cancer management.</p></sec></body><back><notes><title>Funding</title><p>C.-H.L. has received PhD fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research (CIHR) (NHC-142832) and the Public Health Agency of Canada (PHAC). This study is funded by the Ministry of Science and Technology of Taiwan (MOST107-2320-B-038-034-MY3 to L.-T.L.) and the MOST-CNR (National Research Council of Italy) Joint Research Project (MOST107-2911-I-038-501 and MOST108-2911-I-038-501 to L.-T.L. and E.T.).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-12-00852"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>Type W Human Endogenous Retrovirus (HERV-W) Integrations and Their Mobilization by L1 Machinery: Contribution to the Human Transcriptome and Impact on the Host Physiopathology</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.3390/v9070162</pub-id><?supplied-pmid 28653997?><pub-id pub-id-type="pmid">28653997</pub-id></element-citation></ref><ref id="B2-viruses-12-00852"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarchoan</surname><given-names>R.</given-names></name><name><surname>Uldrick</surname><given-names>T.S.</given-names></name></person-group><article-title>HIV-Associated Cancers and Related Diseases</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>1029</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1615896</pub-id><?supplied-pmid 29539283?><pub-id pub-id-type="pmid">29539283</pub-id></element-citation></ref><ref id="B3-viruses-12-00852"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargiu</surname><given-names>L.</given-names></name><name><surname>Rodriguez-Tome</surname><given-names>P.</given-names></name><name><surname>Sperber</surname><given-names>G.O.</given-names></name><name><surname>Cadeddu</surname><given-names>M.</given-names></name><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Blikstad</surname><given-names>V.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name><name><surname>Blomberg</surname><given-names>J.</given-names></name></person-group><article-title>Classification and characterization of human endogenous retroviruses; mosaic forms are common</article-title><source>Retrovirology</source><year>2016</year><volume>13</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12977-015-0232-y</pub-id><?supplied-pmid 26800882?><pub-id pub-id-type="pmid">26800882</pub-id></element-citation></ref><ref id="B4-viruses-12-00852"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>Human Endogenous Retroviruses Are Ancient Acquired Elements Still Shaping Innate Immune Responses</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2039</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02039</pub-id><pub-id pub-id-type="pmid">30250470</pub-id></element-citation></ref><ref id="B5-viruses-12-00852"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>HERV Envelope Proteins: Physiological Role and Pathogenic Potential in Cancer and Autoimmunity</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>462</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00462</pub-id><pub-id pub-id-type="pmid">29593697</pub-id></element-citation></ref><ref id="B6-viruses-12-00852"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Votteler</surname><given-names>J.</given-names></name><name><surname>Schubert</surname><given-names>U.</given-names></name></person-group><article-title>Human Immunodeficiency Viruses: Molecular Biology</article-title><source>Encyclopedia of Virology</source><edition>3rd ed.</edition><person-group person-group-type="editor"><name><surname>Mahy</surname><given-names>B.W.J.</given-names></name><name><surname>van Regenmortel</surname><given-names>M.H.V.</given-names></name></person-group><publisher-name>Elsevier Ltd.</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2008</year><fpage>517</fpage><lpage>525</lpage></element-citation></ref><ref id="B7-viruses-12-00852"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>S.</given-names></name><name><surname>Kupfer</surname><given-names>B.</given-names></name><name><surname>Kaiser</surname><given-names>R.</given-names></name></person-group><article-title>Basics of the virology of HIV-1 and its replication</article-title><source>J. Clin. Virol.</source><year>2005</year><volume>34</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2005.09.004</pub-id><pub-id pub-id-type="pmid">16198625</pub-id></element-citation></ref><ref id="B8-viruses-12-00852"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>W.E.</given-names></name></person-group><article-title>Origins and evolutionary consequences of ancient endogenous retroviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>355</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0189-2</pub-id><pub-id pub-id-type="pmid">30962577</pub-id></element-citation></ref><ref id="B9-viruses-12-00852"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino-Merlo</surname><given-names>F.</given-names></name><name><surname>Balestrieri</surname><given-names>E.</given-names></name><name><surname>Matteucci</surname><given-names>C.</given-names></name><name><surname>Mastino</surname><given-names>A.</given-names></name><name><surname>Grelli</surname><given-names>S.</given-names></name><name><surname>Macchi</surname><given-names>B.</given-names></name></person-group><article-title>Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>342</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9050342</pub-id></element-citation></ref><ref id="B10-viruses-12-00852"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futsch</surname><given-names>N.</given-names></name><name><surname>Mahieux</surname><given-names>R.</given-names></name><name><surname>Dutartre</surname><given-names>H.</given-names></name></person-group><article-title>HTLV-1, the Other Pathogenic yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/v10010001</pub-id></element-citation></ref><ref id="B11-viruses-12-00852"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Center for Infectious Diseases Division of HIV/AIDS</collab><name><surname>Castro</surname><given-names>K.G.</given-names></name><name><surname>Ward</surname><given-names>J.W.</given-names></name><name><surname>Slutsker</surname><given-names>L.</given-names></name><name><surname>Buehler</surname><given-names>J.W.</given-names></name><name><surname>Jaffe</surname><given-names>H.W.</given-names></name><name><surname>Berkelman</surname><given-names>R.L.</given-names></name></person-group><article-title>1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults</article-title><source>MMWR Recomm. Rep.</source><year>1992</year><volume>41</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1093/clinids/17.4.802</pub-id></element-citation></ref><ref id="B12-viruses-12-00852"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Maza</surname><given-names>O.</given-names></name><name><surname>Breen</surname><given-names>E.C.</given-names></name></person-group><article-title>B-cell activation and lymphoma in patients with HIV</article-title><source>Curr. Opin. Oncol.</source><year>2002</year><volume>14</volume><fpage>528</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1097/00001622-200209000-00009</pub-id><pub-id pub-id-type="pmid">12192272</pub-id></element-citation></ref><ref id="B13-viruses-12-00852"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>C.</given-names></name><name><surname>Crane</surname><given-names>H.</given-names></name><name><surname>Menon</surname><given-names>M.</given-names></name><name><surname>Money</surname><given-names>D.</given-names></name></person-group><article-title>HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health</article-title><source>Major Infectious Diseases</source><edition>3rd ed.</edition><person-group person-group-type="editor"><name><surname>Holmes</surname><given-names>K.K.</given-names></name><name><surname>Bertozzi</surname><given-names>S.</given-names></name><name><surname>Bloom</surname><given-names>B.R.</given-names></name><name><surname>Jha</surname><given-names>P.</given-names></name></person-group><publisher-name>The International Bank for Reconstruction and Development/The World Bank</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2017</year><pub-id pub-id-type="doi">10.1596/978-1-4648-0524-0_ch3</pub-id></element-citation></ref><ref id="B14-viruses-12-00852"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Martel</surname><given-names>C.</given-names></name><name><surname>Shiels</surname><given-names>M.S.</given-names></name><name><surname>Franceschi</surname><given-names>S.</given-names></name><name><surname>Simard</surname><given-names>E.P.</given-names></name><name><surname>Vignat</surname><given-names>J.</given-names></name><name><surname>Hall</surname><given-names>H.I.</given-names></name><name><surname>Engels</surname><given-names>E.A.</given-names></name><name><surname>Plummer</surname><given-names>M.</given-names></name></person-group><article-title>Cancers attributable to infections among adults with HIV in the United States</article-title><source>AIDS</source><year>2015</year><volume>29</volume><fpage>2173</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000808</pub-id><?supplied-pmid 26182198?><pub-id pub-id-type="pmid">26182198</pub-id></element-citation></ref><ref id="B15-viruses-12-00852"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubrow</surname><given-names>R.</given-names></name><name><surname>Silverberg</surname><given-names>M.J.</given-names></name><name><surname>Park</surname><given-names>L.S.</given-names></name><name><surname>Crothers</surname><given-names>K.</given-names></name><name><surname>Justice</surname><given-names>A.C.</given-names></name></person-group><article-title>HIV infection, aging, and immune function: Implications for cancer risk and prevention</article-title><source>Curr. Opin. Oncol.</source><year>2012</year><volume>24</volume><fpage>506</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e328355e131</pub-id><?supplied-pmid 22759737?><pub-id pub-id-type="pmid">22759737</pub-id></element-citation></ref><ref id="B16-viruses-12-00852"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlius</surname><given-names>J.</given-names></name><name><surname>Foster</surname><given-names>C.</given-names></name><name><surname>Naidu</surname><given-names>G.</given-names></name><name><surname>Sengayi</surname><given-names>M.</given-names></name><name><surname>Turkova</surname><given-names>A.</given-names></name></person-group><article-title>Cancer in adolescents and young adults living with HIV</article-title><source>Curr. Opin. HIV AIDS</source><year>2018</year><volume>13</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000460</pub-id><pub-id pub-id-type="pmid">29461329</pub-id></element-citation></ref><ref id="B17-viruses-12-00852"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>T.</given-names></name><name><surname>Ponte</surname><given-names>M.</given-names></name><name><surname>Leslie</surname><given-names>K.</given-names></name></person-group><article-title>HIV-associated Kaposi&#x02019;s sarcoma with a high CD4 count and a low viral load</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>357</volume><fpage>1352</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1056/NEJMc070508</pub-id><pub-id pub-id-type="pmid">17898112</pub-id></element-citation></ref><ref id="B18-viruses-12-00852"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>H.A.</given-names></name><name><surname>Shiels</surname><given-names>M.S.</given-names></name><name><surname>Pfeiffer</surname><given-names>R.M.</given-names></name><name><surname>Engels</surname><given-names>E.A.</given-names></name></person-group><article-title>Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>881</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000163</pub-id><pub-id pub-id-type="pmid">24300545</pub-id></element-citation></ref><ref id="B19-viruses-12-00852"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Leeuwen</surname><given-names>M.T.</given-names></name><name><surname>Vajdic</surname><given-names>C.M.</given-names></name><name><surname>Middleton</surname><given-names>M.G.</given-names></name><name><surname>McDonald</surname><given-names>A.M.</given-names></name><name><surname>Law</surname><given-names>M.</given-names></name><name><surname>Kaldor</surname><given-names>J.M.</given-names></name><name><surname>Grulich</surname><given-names>A.E.</given-names></name></person-group><article-title>Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy</article-title><source>AIDS</source><year>2009</year><volume>23</volume><fpage>2183</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328331d384</pub-id><?supplied-pmid 19734774?><pub-id pub-id-type="pmid">19734774</pub-id></element-citation></ref><ref id="B20-viruses-12-00852"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanik</surname><given-names>E.L.</given-names></name><name><surname>Napravnik</surname><given-names>S.</given-names></name><name><surname>Cole</surname><given-names>S.R.</given-names></name><name><surname>Achenbach</surname><given-names>C.J.</given-names></name><name><surname>Gopal</surname><given-names>S.</given-names></name><name><surname>Olshan</surname><given-names>A.</given-names></name><name><surname>Dittmer</surname><given-names>D.P.</given-names></name><name><surname>Kitahata</surname><given-names>M.M.</given-names></name><name><surname>Mugavero</surname><given-names>M.J.</given-names></name><name><surname>Saag</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>57</volume><fpage>756</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1093/cid/cit369</pub-id><pub-id pub-id-type="pmid">23735330</pub-id></element-citation></ref><ref id="B21-viruses-12-00852"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>A.</given-names></name><name><surname>Badoual</surname><given-names>C.</given-names></name><name><surname>Hourseau</surname><given-names>M.</given-names></name><name><surname>Halimi</surname><given-names>C.</given-names></name><name><surname>Pere</surname><given-names>H.</given-names></name><name><surname>Dib</surname><given-names>F.</given-names></name><name><surname>Barry</surname><given-names>B.</given-names></name><name><surname>Albert</surname><given-names>S.</given-names></name></person-group><article-title>Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma</article-title><source>AIDS</source><year>2016</year><volume>30</volume><fpage>1257</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001030</pub-id><pub-id pub-id-type="pmid">26807970</pub-id></element-citation></ref><ref id="B22-viruses-12-00852"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A.B.</given-names></name><name><surname>Darragh</surname><given-names>T.M.</given-names></name><name><surname>Vranizan</surname><given-names>K.</given-names></name><name><surname>Ochia</surname><given-names>C.</given-names></name><name><surname>Moss</surname><given-names>A.R.</given-names></name><name><surname>Palefsky</surname><given-names>J.M.</given-names></name></person-group><article-title>Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women</article-title><source>Obstet. Gynecol.</source><year>1994</year><volume>83</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/0020-7292(94)90475-8</pub-id><pub-id pub-id-type="pmid">8290181</pub-id></element-citation></ref><ref id="B23-viruses-12-00852"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalkowski</surname><given-names>M.A.</given-names></name><name><surname>Mims</surname><given-names>M.A.</given-names></name><name><surname>Day</surname><given-names>R.S.</given-names></name><name><surname>Du</surname><given-names>X.L.</given-names></name><name><surname>Chan</surname><given-names>W.</given-names></name><name><surname>Chiao</surname><given-names>E.Y.</given-names></name></person-group><article-title>Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans</article-title><source>Cancer Epidemiol.</source><year>2014</year><volume>38</volume><fpage>386</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2014.05.009</pub-id><?supplied-pmid 24947588?><pub-id pub-id-type="pmid">24947588</pub-id></element-citation></ref><ref id="B24-viruses-12-00852"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbone</surname><given-names>A.</given-names></name><name><surname>Gloghini</surname><given-names>A.</given-names></name></person-group><article-title>AIDS-related lymphomas: From pathogenesis to pathology</article-title><source>Br. J. Haematol.</source><year>2005</year><volume>130</volume><fpage>662</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05613.x</pub-id><?supplied-pmid 16115121?><pub-id pub-id-type="pmid">16115121</pub-id></element-citation></ref><ref id="B25-viruses-12-00852"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coghill</surname><given-names>A.E.</given-names></name><name><surname>Shiels</surname><given-names>M.S.</given-names></name><name><surname>Suneja</surname><given-names>G.</given-names></name><name><surname>Engels</surname><given-names>E.A.</given-names></name></person-group><article-title>Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>2376</fpage><lpage>2383</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.5967</pub-id><?supplied-pmid 26077242?><pub-id pub-id-type="pmid">26077242</pub-id></element-citation></ref><ref id="B26-viruses-12-00852"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigel</surname><given-names>K.</given-names></name><name><surname>Makinson</surname><given-names>A.</given-names></name><name><surname>Thaler</surname><given-names>J.</given-names></name></person-group><article-title>Lung cancer in persons with HIV</article-title><source>Curr. Opin. HIV AIDS</source><year>2017</year><volume>12</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000326</pub-id><?supplied-pmid 27607596?><pub-id pub-id-type="pmid">27607596</pub-id></element-citation></ref><ref id="B27-viruses-12-00852"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mdodo</surname><given-names>R.</given-names></name><name><surname>Frazier</surname><given-names>E.L.</given-names></name><name><surname>Dube</surname><given-names>S.R.</given-names></name><name><surname>Mattson</surname><given-names>C.L.</given-names></name><name><surname>Sutton</surname><given-names>M.Y.</given-names></name><name><surname>Brooks</surname><given-names>J.T.</given-names></name><name><surname>Skarbinski</surname><given-names>J.</given-names></name></person-group><article-title>Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: Cross-sectional surveys</article-title><source>Ann. Intern. Med.</source><year>2015</year><volume>162</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.7326/M14-0954</pub-id><?supplied-pmid 25732274?><pub-id pub-id-type="pmid">25732274</pub-id></element-citation></ref><ref id="B28-viruses-12-00852"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shebl</surname><given-names>F.M.</given-names></name><name><surname>Engels</surname><given-names>E.A.</given-names></name><name><surname>Goedert</surname><given-names>J.J.</given-names></name><name><surname>Chaturvedi</surname><given-names>A.K.</given-names></name></person-group><article-title>Pulmonary infections and risk of lung cancer among persons with AIDS</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2010</year><volume>55</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181eef4f7</pub-id><pub-id pub-id-type="pmid">20736841</pub-id></element-citation></ref><ref id="B29-viruses-12-00852"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>G.M.</given-names></name><name><surname>Lise</surname><given-names>M.</given-names></name><name><surname>Franceschi</surname><given-names>S.</given-names></name><name><surname>Egger</surname><given-names>M.</given-names></name><name><surname>Bouchardy</surname><given-names>C.</given-names></name><name><surname>Korol</surname><given-names>D.</given-names></name><name><surname>Levi</surname><given-names>F.</given-names></name><name><surname>Ess</surname><given-names>S.</given-names></name><name><surname>Jundt</surname><given-names>G.</given-names></name><name><surname>Wandeler</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection</article-title><source>Br. J. Cancer</source><year>2012</year><volume>106</volume><fpage>447</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.558</pub-id><pub-id pub-id-type="pmid">22240797</pub-id></element-citation></ref><ref id="B30-viruses-12-00852"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puronen</surname><given-names>C.E.</given-names></name><name><surname>Ford</surname><given-names>E.S.</given-names></name><name><surname>Uldrick</surname><given-names>T.S.</given-names></name></person-group><article-title>Immunotherapy in People with HIV and Cancer</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2060</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02060</pub-id><pub-id pub-id-type="pmid">31555284</pub-id></element-citation></ref><ref id="B31-viruses-12-00852"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Pisano</surname><given-names>M.P.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>The emerging field of human endogenous retroviruses: Understanding their physiological role and contribution to diseases</article-title><source>Future Virol.</source><year>2019</year><volume>14</volume><fpage>441</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.2217/fvl-2019-0061</pub-id></element-citation></ref><ref id="B32-viruses-12-00852"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallet</surname><given-names>F.</given-names></name><name><surname>Bouton</surname><given-names>O.</given-names></name><name><surname>Prudhomme</surname><given-names>S.</given-names></name><name><surname>Cheynet</surname><given-names>V.</given-names></name><name><surname>Oriol</surname><given-names>G.</given-names></name><name><surname>Bonnaud</surname><given-names>B.</given-names></name><name><surname>Lucotte</surname><given-names>G.</given-names></name><name><surname>Duret</surname><given-names>L.</given-names></name><name><surname>Mandrand</surname><given-names>B.</given-names></name></person-group><article-title>The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>1731</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1073/pnas.0305763101</pub-id><pub-id pub-id-type="pmid">14757826</pub-id></element-citation></ref><ref id="B33-viruses-12-00852"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaise</surname><given-names>S.</given-names></name><name><surname>de Parseval</surname><given-names>N.</given-names></name><name><surname>Benit</surname><given-names>L.</given-names></name><name><surname>Heidmann</surname><given-names>T.</given-names></name></person-group><article-title>Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>13013</fpage><lpage>13018</lpage><pub-id pub-id-type="doi">10.1073/pnas.2132646100</pub-id><?supplied-pmid 14557543?><pub-id pub-id-type="pmid">14557543</pub-id></element-citation></ref><ref id="B34-viruses-12-00852"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangeney</surname><given-names>M.</given-names></name><name><surname>Renard</surname><given-names>M.</given-names></name><name><surname>Schlecht-Louf</surname><given-names>G.</given-names></name><name><surname>Bouallaga</surname><given-names>I.</given-names></name><name><surname>Heidmann</surname><given-names>O.</given-names></name><name><surname>Letzelter</surname><given-names>C.</given-names></name><name><surname>Richaud</surname><given-names>A.</given-names></name><name><surname>Ducos</surname><given-names>B.</given-names></name><name><surname>Heidmann</surname><given-names>T.</given-names></name></person-group><article-title>Placental syncytins: Genetic disjunction between the fusogenic and immunosuppressive activity of retroviral envelope proteins</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>20534</fpage><lpage>20539</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707873105</pub-id><?supplied-pmid 18077339?><pub-id pub-id-type="pmid">18077339</pub-id></element-citation></ref><ref id="B35-viruses-12-00852"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolosa</surname><given-names>J.M.</given-names></name><name><surname>Schjenken</surname><given-names>J.E.</given-names></name><name><surname>Clifton</surname><given-names>V.L.</given-names></name><name><surname>Vargas</surname><given-names>A.</given-names></name><name><surname>Barbeau</surname><given-names>B.</given-names></name><name><surname>Lowry</surname><given-names>P.</given-names></name><name><surname>Maiti</surname><given-names>K.</given-names></name><name><surname>Smith</surname><given-names>R.</given-names></name></person-group><article-title>The endogenous retroviral envelope protein syncytin-1 inhibits LPS/PHA-stimulated cytokine responses in human blood and is sorted into placental exosomes</article-title><source>Placenta</source><year>2012</year><volume>33</volume><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.placenta.2012.08.004</pub-id><?supplied-pmid 22999499?><pub-id pub-id-type="pmid">22999499</pub-id></element-citation></ref><ref id="B36-viruses-12-00852"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavialle</surname><given-names>C.</given-names></name><name><surname>Cornelis</surname><given-names>G.</given-names></name><name><surname>Dupressoir</surname><given-names>A.</given-names></name><name><surname>Esnault</surname><given-names>C.</given-names></name><name><surname>Heidmann</surname><given-names>O.</given-names></name><name><surname>Vernochet</surname><given-names>C.</given-names></name><name><surname>Heidmann</surname><given-names>T.</given-names></name></person-group><article-title>Paleovirology of &#x02018;<italic>syncytins</italic>&#x02019;, retroviral <italic>env</italic> genes exapted for a role in placentation</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2013</year><volume>368</volume><fpage>20120507</fpage><pub-id pub-id-type="doi">10.1098/rstb.2012.0507</pub-id></element-citation></ref><ref id="B37-viruses-12-00852"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esnault</surname><given-names>C.</given-names></name><name><surname>Cornelis</surname><given-names>G.</given-names></name><name><surname>Heidmann</surname><given-names>O.</given-names></name><name><surname>Heidmann</surname><given-names>T.</given-names></name></person-group><article-title>Differential Evolutionary Fate of an Ancestral Primate Endogenous Retrovirus Envelope Gene, the EnvV <italic>Syncytin</italic>, Captured for a Function in Placentation</article-title><source>PLoS Genet.</source><year>2013</year><volume>9</volume><elocation-id>e1003400</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003400</pub-id><pub-id pub-id-type="pmid">23555306</pub-id></element-citation></ref><ref id="B38-viruses-12-00852"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlesinger</surname><given-names>S.</given-names></name><name><surname>Goff</surname><given-names>S.P.</given-names></name></person-group><article-title>Retroviral transcriptional regulation and embryonic stem cells: War and peace</article-title><source>Mol. Cell. Biol.</source><year>2015</year><volume>35</volume><fpage>770</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1128/MCB.01293-14</pub-id><pub-id pub-id-type="pmid">25547290</pub-id></element-citation></ref><ref id="B39-viruses-12-00852"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifarth</surname><given-names>W.</given-names></name><name><surname>Frank</surname><given-names>O.</given-names></name><name><surname>Zeilfelder</surname><given-names>U.</given-names></name><name><surname>Spiess</surname><given-names>B.</given-names></name><name><surname>Greenwood</surname><given-names>A.D.</given-names></name><name><surname>Hehlmann</surname><given-names>R.</given-names></name><name><surname>Leib-Mosch</surname><given-names>C.</given-names></name></person-group><article-title>Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.1.341-352.2005</pub-id><pub-id pub-id-type="pmid">15596828</pub-id></element-citation></ref><ref id="B40-viruses-12-00852"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavie</surname><given-names>L.</given-names></name><name><surname>Kitova</surname><given-names>M.</given-names></name><name><surname>Maldener</surname><given-names>E.</given-names></name><name><surname>Meese</surname><given-names>E.</given-names></name><name><surname>Mayer</surname><given-names>J.</given-names></name></person-group><article-title>CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2)</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>876</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.2.876-883.2005</pub-id><pub-id pub-id-type="pmid">15613316</pub-id></element-citation></ref><ref id="B41-viruses-12-00852"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downey</surname><given-names>R.F.</given-names></name><name><surname>Sullivan</surname><given-names>F.J.</given-names></name><name><surname>Wang-Johanning</surname><given-names>F.</given-names></name><name><surname>Ambs</surname><given-names>S.</given-names></name><name><surname>Giles</surname><given-names>F.J.</given-names></name><name><surname>Glynn</surname><given-names>S.A.</given-names></name></person-group><article-title>Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?</article-title><source>Int. J. Cancer</source><year>2015</year><volume>137</volume><fpage>1249</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1002/ijc.29003</pub-id><pub-id pub-id-type="pmid">24890612</pub-id></element-citation></ref><ref id="B42-viruses-12-00852"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenig</surname><given-names>M.</given-names></name></person-group><article-title>HERVs, immunity, and autoimmunity: Understanding the connection</article-title><source>PeerJ</source><year>2019</year><volume>7</volume><fpage>e6711</fpage><pub-id pub-id-type="doi">10.7717/peerj.6711</pub-id><pub-id pub-id-type="pmid">30984482</pub-id></element-citation></ref><ref id="B43-viruses-12-00852"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kury</surname><given-names>P.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name><name><surname>Creange</surname><given-names>A.</given-names></name><name><surname>Dolei</surname><given-names>A.</given-names></name><name><surname>Marche</surname><given-names>P.</given-names></name><name><surname>Gold</surname><given-names>J.</given-names></name><name><surname>Giovannoni</surname><given-names>G.</given-names></name><name><surname>Hartung</surname><given-names>H.P.</given-names></name><name><surname>Perron</surname><given-names>H.</given-names></name></person-group><article-title>Human Endogenous Retroviruses in Neurological Diseases</article-title><source>Trends Mol. Med.</source><year>2018</year><volume>24</volume><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2018.02.007</pub-id><?supplied-pmid 29551251?><pub-id pub-id-type="pmid">29551251</pub-id></element-citation></ref><ref id="B44-viruses-12-00852"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matteucci</surname><given-names>C.</given-names></name><name><surname>Balestrieri</surname><given-names>E.</given-names></name><name><surname>Argaw-Denboba</surname><given-names>A.</given-names></name><name><surname>Sinibaldi-Vallebona</surname><given-names>P.</given-names></name></person-group><article-title>Human endogenous retroviruses role in cancer cell stemness</article-title><source>Semin. Cancer Biol.</source><year>2018</year><volume>53</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2018.10.001</pub-id><?supplied-pmid 30317035?><pub-id pub-id-type="pmid">30317035</pub-id></element-citation></ref><ref id="B45-viruses-12-00852"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Foroozesh</surname><given-names>M.</given-names></name><name><surname>Qin</surname><given-names>Z.</given-names></name></person-group><article-title>Transactivation of human endogenous retroviruses by tumor viruses and their functions in virus-associated malignancies</article-title><source>Oncogenesis</source><year>2019</year><volume>8</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41389-018-0114-y</pub-id><?supplied-pmid 30643113?><pub-id pub-id-type="pmid">30643113</pub-id></element-citation></ref><ref id="B46-viruses-12-00852"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>J.Q.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name></person-group><article-title>Expressional activation and functional roles of human endogenous retroviruses in cancers</article-title><source>Rev. Med. Virol.</source><year>2019</year><volume>29</volume><fpage>e2025</fpage><pub-id pub-id-type="doi">10.1002/rmv.2025</pub-id><pub-id pub-id-type="pmid">30614117</pub-id></element-citation></ref><ref id="B47-viruses-12-00852"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attermann</surname><given-names>A.S.</given-names></name><name><surname>Bjerregaard</surname><given-names>A.M.</given-names></name><name><surname>Saini</surname><given-names>S.K.</given-names></name><name><surname>Gronbaek</surname><given-names>K.</given-names></name><name><surname>Hadrup</surname><given-names>S.R.</given-names></name></person-group><article-title>Human endogenous retroviruses and their implication for immunotherapeutics of cancer</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>2183</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy413</pub-id><pub-id pub-id-type="pmid">30239576</pub-id></element-citation></ref><ref id="B48-viruses-12-00852"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabski</surname><given-names>D.F.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Rasmussen</surname><given-names>S.K.</given-names></name></person-group><article-title>Close to the Bedside: A Systematic Review of Endogenous Retroviruses and Their Impact in Oncology</article-title><source>J. Surg. Res.</source><year>2019</year><volume>240</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2019.02.009</pub-id><pub-id pub-id-type="pmid">30933828</pub-id></element-citation></ref><ref id="B49-viruses-12-00852"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.C.</given-names></name><name><surname>Beckermann</surname><given-names>K.E.</given-names></name><name><surname>Bortone</surname><given-names>D.S.</given-names></name><name><surname>De Cubas</surname><given-names>A.A.</given-names></name><name><surname>Bixby</surname><given-names>L.M.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Panda</surname><given-names>A.</given-names></name><name><surname>Ganesan</surname><given-names>S.</given-names></name><name><surname>Bhanot</surname><given-names>G.</given-names></name><name><surname>Wallen</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>4804</fpage><lpage>4820</lpage><pub-id pub-id-type="doi">10.1172/JCI121476</pub-id><pub-id pub-id-type="pmid">30137025</pub-id></element-citation></ref><ref id="B50-viruses-12-00852"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rooney</surname><given-names>M.S.</given-names></name><name><surname>Shukla</surname><given-names>S.A.</given-names></name><name><surname>Wu</surname><given-names>C.J.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name><name><surname>Hacohen</surname><given-names>N.</given-names></name></person-group><article-title>Molecular and genetic properties of tumors associated with local immune cytolytic activity</article-title><source>Cell</source><year>2015</year><volume>160</volume><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.12.033</pub-id><pub-id pub-id-type="pmid">25594174</pub-id></element-citation></ref><ref id="B51-viruses-12-00852"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergallo</surname><given-names>M.</given-names></name><name><surname>Montanari</surname><given-names>P.</given-names></name><name><surname>Mareschi</surname><given-names>K.</given-names></name><name><surname>Merlino</surname><given-names>C.</given-names></name><name><surname>Berger</surname><given-names>M.</given-names></name><name><surname>Bini</surname><given-names>I.</given-names></name><name><surname>Dapra</surname><given-names>V.</given-names></name><name><surname>Galliano</surname><given-names>I.</given-names></name><name><surname>Fagioli</surname><given-names>F.</given-names></name></person-group><article-title>Expression of the <italic>pol</italic> gene of human endogenous retroviruses HERV-K and -W in leukemia patients</article-title><source>Arch. Virol.</source><year>2017</year><volume>162</volume><fpage>3639</fpage><lpage>3644</lpage><pub-id pub-id-type="doi">10.1007/s00705-017-3526-7</pub-id><pub-id pub-id-type="pmid">28821995</pub-id></element-citation></ref><ref id="B52-viruses-12-00852"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januszkiewicz-Lewandowska</surname><given-names>D.</given-names></name><name><surname>Nowicka</surname><given-names>K.</given-names></name><name><surname>Rembowska</surname><given-names>J.</given-names></name><name><surname>Fichna</surname><given-names>M.</given-names></name><name><surname>Zurawek</surname><given-names>M.</given-names></name><name><surname>Derwich</surname><given-names>K.</given-names></name><name><surname>Nowak</surname><given-names>J.</given-names></name></person-group><article-title><italic>Env</italic> gene expression of human endogenous retrovirus-k and human endogenous retrovirus-w in childhood acute leukemia cells</article-title><source>Acta Haematol.</source><year>2013</year><volume>129</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1159/000345407</pub-id><pub-id pub-id-type="pmid">23328642</pub-id></element-citation></ref><ref id="B53-viruses-12-00852"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassiotis</surname><given-names>G.</given-names></name><name><surname>Stoye</surname><given-names>J.P.</given-names></name></person-group><article-title>Making a virtue of necessity: The pleiotropic role of human endogenous retroviruses in cancer</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2017</year><volume>372</volume><fpage>20160277</fpage><pub-id pub-id-type="doi">10.1098/rstb.2016.0277</pub-id><?supplied-pmid 28893944?><pub-id pub-id-type="pmid">28893944</pub-id></element-citation></ref><ref id="B54-viruses-12-00852"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannert</surname><given-names>N.</given-names></name><name><surname>Hofmann</surname><given-names>H.</given-names></name><name><surname>Block</surname><given-names>A.</given-names></name><name><surname>Hohn</surname><given-names>O.</given-names></name></person-group><article-title>HERVs New Role in Cancer: From Accused Perpetrators to Cheerful Protectors</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>178</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00178</pub-id><?supplied-pmid 29487579?><pub-id pub-id-type="pmid">29487579</pub-id></element-citation></ref><ref id="B55-viruses-12-00852"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlins</surname><given-names>S.A.</given-names></name><name><surname>Laxman</surname><given-names>B.</given-names></name><name><surname>Dhanasekaran</surname><given-names>S.M.</given-names></name><name><surname>Helgeson</surname><given-names>B.E.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Morris</surname><given-names>D.S.</given-names></name><name><surname>Menon</surname><given-names>A.</given-names></name><name><surname>Jing</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nature06024</pub-id><?supplied-pmid 17671502?><pub-id pub-id-type="pmid">17671502</pub-id></element-citation></ref><ref id="B56-viruses-12-00852"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mareschi</surname><given-names>K.</given-names></name><name><surname>Montanari</surname><given-names>P.</given-names></name><name><surname>Rassu</surname><given-names>M.</given-names></name><name><surname>Galliano</surname><given-names>I.</given-names></name><name><surname>Dapra</surname><given-names>V.</given-names></name><name><surname>Adamini</surname><given-names>A.</given-names></name><name><surname>Castiglia</surname><given-names>S.</given-names></name><name><surname>Fagioli</surname><given-names>F.</given-names></name><name><surname>Bergallo</surname><given-names>M.</given-names></name></person-group><article-title>Human Endogenous Retrovirus-H and K Expression in Human Mesenchymal Stem Cells as Potential Markers of Stemness</article-title><source>Intervirology</source><year>2019</year><volume>62</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1159/000499185</pub-id><pub-id pub-id-type="pmid">31104062</pub-id></element-citation></ref><ref id="B57-viruses-12-00852"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Carballo</surname><given-names>D.</given-names></name><name><surname>Acikelli</surname><given-names>A.H.</given-names></name><name><surname>Klein</surname><given-names>J.</given-names></name><name><surname>Jastrow</surname><given-names>H.</given-names></name><name><surname>Dammann</surname><given-names>P.</given-names></name><name><surname>Wyganowski</surname><given-names>T.</given-names></name><name><surname>Guemues</surname><given-names>C.</given-names></name><name><surname>Gustmann</surname><given-names>S.</given-names></name><name><surname>Bardenheuer</surname><given-names>W.</given-names></name><name><surname>Malak</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2015</year><volume>34</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s13046-015-0199-5</pub-id><pub-id pub-id-type="pmid">26260344</pub-id></element-citation></ref><ref id="B58-viruses-12-00852"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argaw-Denboba</surname><given-names>A.</given-names></name><name><surname>Balestrieri</surname><given-names>E.</given-names></name><name><surname>Serafino</surname><given-names>A.</given-names></name><name><surname>Cipriani</surname><given-names>C.</given-names></name><name><surname>Bucci</surname><given-names>I.</given-names></name><name><surname>Sorrentino</surname><given-names>R.</given-names></name><name><surname>Sciamanna</surname><given-names>I.</given-names></name><name><surname>Gambacurta</surname><given-names>A.</given-names></name><name><surname>Sinibaldi-Vallebona</surname><given-names>P.</given-names></name><name><surname>Matteucci</surname><given-names>C.</given-names></name></person-group><article-title>HERV-K activation is strictly required to sustain CD133<sup>+</sup> melanoma cells with stemness features</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0485-x</pub-id><pub-id pub-id-type="pmid">28125999</pub-id></element-citation></ref><ref id="B59-viruses-12-00852"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Johanning</surname><given-names>G.L.</given-names></name><name><surname>Wang-Johanning</surname><given-names>F.</given-names></name></person-group><article-title>Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>84093</fpage><lpage>84117</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11455</pub-id><pub-id pub-id-type="pmid">27557521</pub-id></element-citation></ref><ref id="B60-viruses-12-00852"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Johanning</surname><given-names>F.</given-names></name><name><surname>Rycaj</surname><given-names>K.</given-names></name><name><surname>Plummer</surname><given-names>J.B.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Frerich</surname><given-names>K.</given-names></name><name><surname>Garza</surname><given-names>J.G.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Yan</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors</article-title><source>J. Natl. Cancer Inst.</source><year>2012</year><volume>104</volume><fpage>189</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr540</pub-id><pub-id pub-id-type="pmid">22247020</pub-id></element-citation></ref><ref id="B61-viruses-12-00852"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Krishnamurthy</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Hunt</surname><given-names>K.</given-names></name><name><surname>Johanning</surname><given-names>G.L.</given-names></name><name><surname>Cooper</surname><given-names>L.J.</given-names></name><name><surname>Wang-Johanning</surname><given-names>F.</given-names></name></person-group><article-title>Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras</article-title><source>Oncoimmunology</source><year>2015</year><volume>4</volume><fpage>e1047582</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1047582</pub-id><pub-id pub-id-type="pmid">26451325</pub-id></element-citation></ref><ref id="B62-viruses-12-00852"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavetti</surname><given-names>F.</given-names></name><name><surname>Thonnard</surname><given-names>J.</given-names></name><name><surname>Colau</surname><given-names>D.</given-names></name><name><surname>Boon</surname><given-names>T.</given-names></name><name><surname>Coulie</surname><given-names>P.G.</given-names></name></person-group><article-title>A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>5510</fpage><lpage>5516</lpage><pub-id pub-id-type="pmid">12359761</pub-id></element-citation></ref><ref id="B63-viruses-12-00852"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>J.</given-names></name><name><surname>Rabinovich</surname><given-names>B.A.</given-names></name><name><surname>Mi</surname><given-names>T.</given-names></name><name><surname>Switzer</surname><given-names>K.C.</given-names></name><name><surname>Olivares</surname><given-names>S.</given-names></name><name><surname>Maiti</surname><given-names>S.N.</given-names></name><name><surname>Plummer</surname><given-names>J.B.</given-names></name><name><surname>Singh</surname><given-names>H.</given-names></name><name><surname>Kumaresan</surname><given-names>P.R.</given-names></name><name><surname>Huls</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>3241</fpage><lpage>3251</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-3197</pub-id><?supplied-pmid 25829402?><pub-id pub-id-type="pmid">25829402</pub-id></element-citation></ref><ref id="B64-viruses-12-00852"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Radvanyi</surname><given-names>L.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Rycaj</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Chivukula</surname><given-names>R.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Chang</surname><given-names>D.Z.</given-names></name><etal/></person-group><article-title>Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral <italic>env</italic> RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>5892</fpage><lpage>5911</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0001</pub-id><?supplied-pmid 28679769?><pub-id pub-id-type="pmid">28679769</pub-id></element-citation></ref><ref id="B65-viruses-12-00852"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo-Saito</surname><given-names>C.</given-names></name><name><surname>Yura</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>R.</given-names></name><name><surname>Kawakami</surname><given-names>Y.</given-names></name></person-group><article-title>Induction of immunoregulatory CD271<sup>+</sup> cells by metastatic tumor cells that express human endogenous retrovirus H</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>1361</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1349</pub-id><pub-id pub-id-type="pmid">24590808</pub-id></element-citation></ref><ref id="B66-viruses-12-00852"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denne</surname><given-names>M.</given-names></name><name><surname>Sauter</surname><given-names>M.</given-names></name><name><surname>Armbruester</surname><given-names>V.</given-names></name><name><surname>Licht</surname><given-names>J.D.</given-names></name><name><surname>Roemer</surname><given-names>K.</given-names></name><name><surname>Mueller-Lantzsch</surname><given-names>N.</given-names></name></person-group><article-title>Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>5607</fpage><lpage>5616</lpage><pub-id pub-id-type="doi">10.1128/JVI.02771-06</pub-id><?supplied-pmid 17360752?><pub-id pub-id-type="pmid">17360752</pub-id></element-citation></ref><ref id="B67-viruses-12-00852"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>S.</given-names></name><name><surname>Sauter</surname><given-names>M.</given-names></name><name><surname>Schmitt</surname><given-names>M.</given-names></name><name><surname>Baumert</surname><given-names>B.</given-names></name><name><surname>Best</surname><given-names>B.</given-names></name><name><surname>Boese</surname><given-names>A.</given-names></name><name><surname>Roemer</surname><given-names>K.</given-names></name><name><surname>Mueller-Lantzsch</surname><given-names>N.</given-names></name></person-group><article-title>Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor</article-title><source>J. Gen. Virol.</source><year>2010</year><volume>91</volume><fpage>1494</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1099/vir.0.014241-0</pub-id><pub-id pub-id-type="pmid">20147518</pub-id></element-citation></ref><ref id="B68-viruses-12-00852"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanke</surname><given-names>K.</given-names></name><name><surname>Chudak</surname><given-names>C.</given-names></name><name><surname>Kurth</surname><given-names>R.</given-names></name><name><surname>Bannert</surname><given-names>N.</given-names></name></person-group><article-title>The Rec protein of HERV-K(HML-2) upregulates androgen receptor activity by binding to the human small glutamine-rich tetratricopeptide repeat protein (hSGT)</article-title><source>Int. J. Cancer</source><year>2013</year><volume>132</volume><fpage>556</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1002/ijc.27693</pub-id><pub-id pub-id-type="pmid">22733359</pub-id></element-citation></ref><ref id="B69-viruses-12-00852"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armbruester</surname><given-names>V.</given-names></name><name><surname>Sauter</surname><given-names>M.</given-names></name><name><surname>Roemer</surname><given-names>K.</given-names></name><name><surname>Best</surname><given-names>B.</given-names></name><name><surname>Hahn</surname><given-names>S.</given-names></name><name><surname>Nty</surname><given-names>A.</given-names></name><name><surname>Schmid</surname><given-names>A.</given-names></name><name><surname>Philipp</surname><given-names>S.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Mueller-Lantzsch</surname><given-names>N.</given-names></name></person-group><article-title>Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>10310</fpage><lpage>10319</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.19.10310-10319.2004</pub-id><pub-id pub-id-type="pmid">15367597</pub-id></element-citation></ref><ref id="B70-viruses-12-00852"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Cadeddu</surname><given-names>M.</given-names></name><name><surname>Pisano</surname><given-names>M.P.</given-names></name><name><surname>Esposito</surname><given-names>F.</given-names></name><name><surname>Blomberg</surname><given-names>J.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>Identification of a novel HERV-K(HML<sub>10</sub>): Comprehensive characterization and comparative analysis in non-human primates provide insights about HML<sub>10</sub> proviruses structure and diffusion</article-title><source>Mob. DNA</source><year>2017</year><volume>8</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13100-017-0099-7</pub-id><pub-id pub-id-type="pmid">29118853</pub-id></element-citation></ref><ref id="B71-viruses-12-00852"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisano</surname><given-names>M.P.</given-names></name><name><surname>Grandi</surname><given-names>N.</given-names></name><name><surname>Cadeddu</surname><given-names>M.</given-names></name><name><surname>Blomberg</surname><given-names>J.</given-names></name><name><surname>Tramontano</surname><given-names>E.</given-names></name></person-group><article-title>Comprehensive Characterization of the Human Endogenous Retrovirus HERV-K(HML-6) Group: Overview of Structure, Phylogeny, and Contribution to the Human Genome</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>e00110-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.00110-19</pub-id><pub-id pub-id-type="pmid">31167914</pub-id></element-citation></ref><ref id="B72-viruses-12-00852"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakoff-Nahoum</surname><given-names>S.</given-names></name><name><surname>Kuebler</surname><given-names>P.J.</given-names></name><name><surname>Heymann</surname><given-names>J.J.</given-names></name><name><surname>Sheehy</surname><given-names>M.E.</given-names></name><name><surname>Ortiz</surname><given-names>G.M.</given-names></name><name><surname>Ogg</surname><given-names>G.S.</given-names></name><name><surname>Barbour</surname><given-names>J.D.</given-names></name><name><surname>Lenz</surname><given-names>J.</given-names></name><name><surname>Steinfeld</surname><given-names>A.D.</given-names></name><name><surname>Nixon</surname><given-names>D.F.</given-names></name></person-group><article-title>Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2006</year><volume>22</volume><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1089/aid.2006.22.52</pub-id><pub-id pub-id-type="pmid">16438646</pub-id></element-citation></ref><ref id="B73-viruses-12-00852"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Harashima</surname><given-names>N.</given-names></name><name><surname>Kajigaya</surname><given-names>S.</given-names></name><name><surname>Yokoyama</surname><given-names>H.</given-names></name><name><surname>Cherkasova</surname><given-names>E.</given-names></name><name><surname>McCoy</surname><given-names>J.P.</given-names></name><name><surname>Hanada</surname><given-names>K.</given-names></name><name><surname>Mena</surname><given-names>O.</given-names></name><name><surname>Kurlander</surname><given-names>R.</given-names></name><name><surname>Tawab</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells</article-title><source>J. Clin. Investig.</source><year>2008</year><volume>118</volume><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1172/JCI34409C1</pub-id><?supplied-pmid 18292810?><pub-id pub-id-type="pmid">18292810</pub-id></element-citation></ref><ref id="B74-viruses-12-00852"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiman</surname><given-names>A.</given-names></name><name><surname>Senyuta</surname><given-names>N.</given-names></name><name><surname>Tryakin</surname><given-names>A.</given-names></name><name><surname>Sauter</surname><given-names>M.</given-names></name><name><surname>Karseladze</surname><given-names>A.</given-names></name><name><surname>Tjulandin</surname><given-names>S.</given-names></name><name><surname>Gurtsevitch</surname><given-names>V.</given-names></name><name><surname>Mueller-Lantzsch</surname><given-names>N.</given-names></name></person-group><article-title>HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors</article-title><source>Int. J. Cancer</source><year>2004</year><volume>110</volume><fpage>459</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/ijc.11649</pub-id><pub-id pub-id-type="pmid">15095315</pub-id></element-citation></ref><ref id="B75-viruses-12-00852"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>S.</given-names></name><name><surname>Ugurel</surname><given-names>S.</given-names></name><name><surname>Hanschmann</surname><given-names>K.M.</given-names></name><name><surname>Strobel</surname><given-names>H.</given-names></name><name><surname>Tondera</surname><given-names>C.</given-names></name><name><surname>Schadendorf</surname><given-names>D.</given-names></name><name><surname>Lower</surname><given-names>J.</given-names></name><name><surname>Lower</surname><given-names>R.</given-names></name></person-group><article-title>Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2008</year><volume>24</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1089/aid.2007.0286</pub-id><?supplied-pmid 18462078?><pub-id pub-id-type="pmid">18462078</pub-id></element-citation></ref><ref id="B76-viruses-12-00852"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>T.P.</given-names></name><name><surname>Magiorkinis</surname><given-names>G.</given-names></name></person-group><article-title>Activation of the innate immune response by endogenous retroviruses</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>1207</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000017</pub-id><?supplied-pmid 26068187?><pub-id pub-id-type="pmid">26068187</pub-id></element-citation></ref><ref id="B77-viruses-12-00852"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolland</surname><given-names>A.</given-names></name><name><surname>Jouvin-Marche</surname><given-names>E.</given-names></name><name><surname>Viret</surname><given-names>C.</given-names></name><name><surname>Faure</surname><given-names>M.</given-names></name><name><surname>Perron</surname><given-names>H.</given-names></name><name><surname>Marche</surname><given-names>P.N.</given-names></name></person-group><article-title>The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses</article-title><source>J. Immunol.</source><year>2006</year><volume>176</volume><fpage>7636</fpage><lpage>7644</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.12.7636</pub-id><pub-id pub-id-type="pmid">16751411</pub-id></element-citation></ref><ref id="B78-viruses-12-00852"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A.K.</given-names></name><name><surname>Pan</surname><given-names>D.</given-names></name><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>C.Y.</given-names></name></person-group><article-title>Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy</article-title><source>Radiat. Res.</source><year>2020</year><volume>193</volume><fpage>305</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1667/RADE-20-00013</pub-id><pub-id pub-id-type="pmid">32074012</pub-id></element-citation></ref><ref id="B79-viruses-12-00852"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perron</surname><given-names>H.</given-names></name><name><surname>Germi</surname><given-names>R.</given-names></name><name><surname>Bernard</surname><given-names>C.</given-names></name><name><surname>Garcia-Montojo</surname><given-names>M.</given-names></name><name><surname>Deluen</surname><given-names>C.</given-names></name><name><surname>Farinelli</surname><given-names>L.</given-names></name><name><surname>Faucard</surname><given-names>R.</given-names></name><name><surname>Veas</surname><given-names>F.</given-names></name><name><surname>Stefas</surname><given-names>I.</given-names></name><name><surname>Fabriek</surname><given-names>B.O.</given-names></name><etal/></person-group><article-title>Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease</article-title><source>Mult. Scler. J.</source><year>2012</year><volume>18</volume><fpage>1721</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1177/1352458512441381</pub-id></element-citation></ref><ref id="B80-viruses-12-00852"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laska</surname><given-names>M.J.</given-names></name><name><surname>Brudek</surname><given-names>T.</given-names></name><name><surname>Nissen</surname><given-names>K.K.</given-names></name><name><surname>Christensen</surname><given-names>T.</given-names></name><name><surname>Moller-Larsen</surname><given-names>A.</given-names></name><name><surname>Petersen</surname><given-names>T.</given-names></name><name><surname>Nexo</surname><given-names>B.A.</given-names></name></person-group><article-title>Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>3713</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1128/JVI.06723-11</pub-id><pub-id pub-id-type="pmid">22278236</pub-id></element-citation></ref><ref id="B81-viruses-12-00852"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diebold</surname><given-names>M.</given-names></name><name><surname>Derfuss</surname><given-names>T.</given-names></name></person-group><article-title>The monoclonal antibody GNbAC1: Targeting human endogenous retroviruses in multiple sclerosis</article-title><source>Ther. Adv. Neurol. Disord.</source><year>2019</year><volume>12</volume><fpage>1756286419833574</fpage><pub-id pub-id-type="doi">10.1177/1756286419833574</pub-id><pub-id pub-id-type="pmid">30873219</pub-id></element-citation></ref><ref id="B82-viruses-12-00852"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang-Johanning</surname><given-names>F.</given-names></name><name><surname>Radvanyi</surname><given-names>L.</given-names></name><name><surname>Rycaj</surname><given-names>K.</given-names></name><name><surname>Plummer</surname><given-names>J.B.</given-names></name><name><surname>Yan</surname><given-names>P.</given-names></name><name><surname>Sastry</surname><given-names>K.J.</given-names></name><name><surname>Piyathilake</surname><given-names>C.J.</given-names></name><name><surname>Hunt</surname><given-names>K.K.</given-names></name><name><surname>Johanning</surname><given-names>G.L.</given-names></name></person-group><article-title>Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>5869</fpage><lpage>5877</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6838</pub-id><pub-id pub-id-type="pmid">18632641</pub-id></element-citation></ref><ref id="B83-viruses-12-00852"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rycaj</surname><given-names>K.</given-names></name><name><surname>Plummer</surname><given-names>J.B.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Garza</surname><given-names>J.</given-names></name><name><surname>Radvanyi</surname><given-names>L.</given-names></name><name><surname>Ramondetta</surname><given-names>L.M.</given-names></name><name><surname>Lin</surname><given-names>K.</given-names></name><name><surname>Johanning</surname><given-names>G.L.</given-names></name><name><surname>Tang</surname><given-names>D.G.</given-names></name><etal/></person-group><article-title>Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>471</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0388</pub-id><?supplied-pmid 25370465?><pub-id pub-id-type="pmid">25370465</pub-id></element-citation></ref><ref id="B84-viruses-12-00852"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherkasova</surname><given-names>E.</given-names></name><name><surname>Scrivani</surname><given-names>C.</given-names></name><name><surname>Doh</surname><given-names>S.</given-names></name><name><surname>Weisman</surname><given-names>Q.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Harashima</surname><given-names>N.</given-names></name><name><surname>Yokoyama</surname><given-names>H.</given-names></name><name><surname>Srinivasan</surname><given-names>R.</given-names></name><name><surname>Linehan</surname><given-names>W.M.</given-names></name><name><surname>Lerman</surname><given-names>M.I.</given-names></name><etal/></person-group><article-title>Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>2177</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3139</pub-id><pub-id pub-id-type="pmid">26862115</pub-id></element-citation></ref><ref id="B85-viruses-12-00852"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>B.</given-names></name><name><surname>Fischer</surname><given-names>K.</given-names></name><name><surname>Buchner</surname><given-names>S.M.</given-names></name><name><surname>Wels</surname><given-names>W.S.</given-names></name><name><surname>Lower</surname><given-names>R.</given-names></name><name><surname>Sliva</surname><given-names>K.</given-names></name><name><surname>Schnierle</surname><given-names>B.S.</given-names></name></person-group><article-title>Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e72756</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072756</pub-id><?supplied-pmid 24023643?><pub-id pub-id-type="pmid">24023643</pub-id></element-citation></ref><ref id="B86-viruses-12-00852"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>B.</given-names></name><name><surname>Fischer</surname><given-names>K.</given-names></name><name><surname>Sliva</surname><given-names>K.</given-names></name><name><surname>Schnierle</surname><given-names>B.S.</given-names></name></person-group><article-title>Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system</article-title><source>Virol. J.</source><year>2014</year><volume>11</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-11-58</pub-id><?supplied-pmid 24669861?><pub-id pub-id-type="pmid">24669861</pub-id></element-citation></ref><ref id="B87-viruses-12-00852"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neukirch</surname><given-names>L.</given-names></name><name><surname>Nielsen</surname><given-names>T.K.</given-names></name><name><surname>Laursen</surname><given-names>H.</given-names></name><name><surname>Daradoumis</surname><given-names>J.</given-names></name><name><surname>Thirion</surname><given-names>C.</given-names></name><name><surname>Holst</surname><given-names>P.J.</given-names></name></person-group><article-title>Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice</article-title><source>Oncotarget</source><year>2019</year><volume>10</volume><fpage>1458</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26680</pub-id><?supplied-pmid 30858929?><pub-id pub-id-type="pmid">30858929</pub-id></element-citation></ref><ref id="B88-viruses-12-00852"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacha</surname><given-names>J.B.</given-names></name><name><surname>Kim</surname><given-names>I.J.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Ullah</surname><given-names>J.H.</given-names></name><name><surname>Goodwin</surname><given-names>D.A.</given-names></name><name><surname>Simmons</surname><given-names>H.A.</given-names></name><name><surname>Schenkman</surname><given-names>D.I.</given-names></name><name><surname>von Pelchrzim</surname><given-names>F.</given-names></name><name><surname>Gifford</surname><given-names>R.J.</given-names></name><name><surname>Nimityongskul</surname><given-names>F.A.</given-names></name><etal/></person-group><article-title>Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>1467</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200079</pub-id><pub-id pub-id-type="pmid">22745376</pub-id></element-citation></ref><ref id="B89-viruses-12-00852"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P.A.</given-names></name><name><surname>Ohtani</surname><given-names>H.</given-names></name><name><surname>Chakravarthy</surname><given-names>A.</given-names></name><name><surname>De Carvalho</surname><given-names>D.D.</given-names></name></person-group><article-title>Epigenetic therapy in immune-oncology</article-title><source>Nat. Rev. Cancer</source><year>2019</year><volume>19</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0109-9</pub-id><pub-id pub-id-type="pmid">30723290</pub-id></element-citation></ref><ref id="B90-viruses-12-00852"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>S.L.</given-names></name><name><surname>DeWitt</surname><given-names>A.K.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Madaj</surname><given-names>Z.B.</given-names></name><name><surname>Ohtani</surname><given-names>H.</given-names></name><name><surname>Baylin</surname><given-names>S.B.</given-names></name><name><surname>Liang</surname><given-names>G.</given-names></name><name><surname>Jones</surname><given-names>P.A.</given-names></name></person-group><article-title>Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells</article-title><source>Cancer Res.</source><year>2018</year><volume>78</volume><fpage>5754</fpage><lpage>5766</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3953</pub-id><pub-id pub-id-type="pmid">30185548</pub-id></element-citation></ref><ref id="B91-viruses-12-00852"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiappinelli</surname><given-names>K.B.</given-names></name><name><surname>Strissel</surname><given-names>P.L.</given-names></name><name><surname>Desrichard</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Henke</surname><given-names>C.</given-names></name><name><surname>Akman</surname><given-names>B.</given-names></name><name><surname>Hein</surname><given-names>A.</given-names></name><name><surname>Rote</surname><given-names>N.S.</given-names></name><name><surname>Cope</surname><given-names>L.M.</given-names></name><name><surname>Snyder</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>974</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.011</pub-id><pub-id pub-id-type="pmid">26317466</pub-id></element-citation></ref><ref id="B92-viruses-12-00852"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wentzensen</surname><given-names>N.</given-names></name><name><surname>Coy</surname><given-names>J.F.</given-names></name><name><surname>Knaebel</surname><given-names>H.P.</given-names></name><name><surname>Linnebacher</surname><given-names>M.</given-names></name><name><surname>Wilz</surname><given-names>B.</given-names></name><name><surname>Gebert</surname><given-names>J.</given-names></name><name><surname>von Knebel Doeberitz</surname><given-names>M.</given-names></name></person-group><article-title>Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers</article-title><source>Int. J. Cancer</source><year>2007</year><volume>121</volume><fpage>1417</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1002/ijc.22826</pub-id><pub-id pub-id-type="pmid">17546591</pub-id></element-citation></ref><ref id="B93-viruses-12-00852"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perot</surname><given-names>P.</given-names></name><name><surname>Mullins</surname><given-names>C.S.</given-names></name><name><surname>Naville</surname><given-names>M.</given-names></name><name><surname>Bressan</surname><given-names>C.</given-names></name><name><surname>Huhns</surname><given-names>M.</given-names></name><name><surname>Gock</surname><given-names>M.</given-names></name><name><surname>Kuhn</surname><given-names>F.</given-names></name><name><surname>Volff</surname><given-names>J.N.</given-names></name><name><surname>Trillet-Lenoir</surname><given-names>V.</given-names></name><name><surname>Linnebacher</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>40095</fpage><lpage>40111</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5539</pub-id><?supplied-pmid 26517682?><pub-id pub-id-type="pmid">26517682</pub-id></element-citation></ref><ref id="B94-viruses-12-00852"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morandi</surname><given-names>E.</given-names></name><name><surname>Tanasescu</surname><given-names>R.</given-names></name><name><surname>Tarlinton</surname><given-names>R.E.</given-names></name><name><surname>Constantin-Teodosiu</surname><given-names>D.</given-names></name><name><surname>Gran</surname><given-names>B.</given-names></name></person-group><article-title>Do Antiretroviral Drugs Protect from Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>3092</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.03092</pub-id><pub-id pub-id-type="pmid">30740110</pub-id></element-citation></ref><ref id="B95-viruses-12-00852"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Parades</surname><given-names>D.</given-names></name><name><surname>Bianchet</surname><given-names>M.A.</given-names></name><name><surname>Nath</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of human endogenous retrovirus-K by antiretroviral drugs</article-title><source>Retrovirology</source><year>2017</year><volume>14</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12977-017-0347-4</pub-id><?supplied-pmid 28330477?><pub-id pub-id-type="pmid">28330477</pub-id></element-citation></ref><ref id="B96-viruses-12-00852"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciamanna</surname><given-names>I.</given-names></name><name><surname>Landriscina</surname><given-names>M.</given-names></name><name><surname>Pittoggi</surname><given-names>C.</given-names></name><name><surname>Quirino</surname><given-names>M.</given-names></name><name><surname>Mearelli</surname><given-names>C.</given-names></name><name><surname>Beraldi</surname><given-names>R.</given-names></name><name><surname>Mattei</surname><given-names>E.</given-names></name><name><surname>Serafino</surname><given-names>A.</given-names></name><name><surname>Cassano</surname><given-names>A.</given-names></name><name><surname>Sinibaldi-Vallebona</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Inhibition of endogenous reverse transcriptase antagonizes human tumor growth</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>3923</fpage><lpage>3931</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208562</pub-id><?supplied-pmid 15806170?><pub-id pub-id-type="pmid">15806170</pub-id></element-citation></ref><ref id="B97-viruses-12-00852"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>R.P.</given-names></name><name><surname>Wildschutte</surname><given-names>J.H.</given-names></name><name><surname>Russo</surname><given-names>C.</given-names></name><name><surname>Coffin</surname><given-names>J.M.</given-names></name></person-group><article-title>Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses</article-title><source>Retrovirology</source><year>2011</year><volume>8</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-8-90</pub-id><?supplied-pmid 22067224?><pub-id pub-id-type="pmid">22067224</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="viruses-12-00852-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Illustration of the HIV&#x02013; and HERV&#x02013;cancer relationships and potential treatment strategies. HIV infection creates a dysregulated environment with chronic inflammation and immunosuppression that aid oncovirus transformation and cancer development (solid red arrows). Strategies to preclude HIV-related cancers include antiretroviral therapies (solid grey T bar) and oncovirus screening/vaccination (solid red T bar). As for HERV, activation and expression of HERV nucleic acid and protein elements have been found in various cancers, potentially contributing to cancer development (solid blue arrows). The aberrant expression of HERV elements has a viral mimicry effect that triggers innate and adaptive immune responses (solid light blue arrows), which have been exploited as approaches to fight HERV-associated cancers (solid light blue T bar). Inducing HERV expression through DNA methyltransferase inhibitors (solid dark blue arrow), immunotherapies targeting HERV proteins (dotted dark blue T bar and solid dark blue arrow), and antiretroviral therapies (dotted grey T bar) are being explored as potential anti-cancer therapies. Figure created with <uri>BioRender.com</uri>.</p></caption><graphic xlink:href="viruses-12-00852-g001"/></fig></floats-group></article>